[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$foR0WRatFvm3KnlOrXsyT2FQATlKTZONV9eokZo-SMYw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"Sunnybrook Health Sciences Centre",[4],572,false,152,39,1375446,50,424,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Breast Cancer",30,{"name":18,"count":19},"Prostate Cancer",25,{"name":21,"count":22},"Stroke",14,{"name":24,"count":25},"Depression",12,{"name":27,"count":28},"Hypertension",11,{"name":30,"count":31},"Alzheimer Disease",10,{"name":33,"count":31},"Major Depressive Disorder",{"name":35,"count":36},"Bipolar Disorder",9,[38,43,48,53,58,63,68,73,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02261415","The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial","2022-08","Tranexamic acid",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05466838","PERT to Improve Quality of Life in Patients Undergoing Pancreaticoduodenectomy: A Pilot Randomized Controlled Trial","2024-05-31","PERT at discharge",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05358639","Combination of Olaparib and Navitoclax in Women with HGSC and TNBC","2025-03-30","Olaparib",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05620290","MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer","2025-07-11","Definity",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05961124","Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer","2025-09","Niraparib",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT04619069","Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer","2025-12","Hormone therapy",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT04624906","Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia","2025-12-31","Acalabrutinib",{"nctId":74,"briefTitle":75,"date":76,"intervention":57},"NCT06185972","Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Breast Cancer","2026-02-01",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06633601","MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast Cancer","2026-03-01","Definity Suspension for",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT04415060","SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival","2026-03-31","Isoflurane Inhalant Product",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,153,179,231,267,313,356,394,432,450,476,494,519,537,562,580,605,645,695,730,755,781,799,824,850,868,886,909,929,954,979,1006,1024,1042,1066,1110,1138,1173,1196,1214,1232,1256,1274,1302,1320,1345,1363,1389,1407,1425,1447,1503,1529,1553,1576,1601,1627,1652,1678,1705,1723,1748,1766,1789,1812,1836,1854,1875,1903,1939,1973,2013,2039,2057,2075,2099,2117,2140,2169,2187,2205,2223,2249,2273,2300,2318,2343,2361,2384,2411,2429,2447,2465,2483,2501,2525,2549,2574,2601,2619,2637,2674,2709,2748,2776,2801,2826,2848,2874,2892,2916,2934,2959,2984,3008,3026,3052,3076,3094,3112,3135,3153,3176,3204,3228,3246,3271,3289,3314,3336,3359,3383,3401,3424,3442,3466,3489,3515,3539,3557,3589,3613,3631,3656,3682,3700,3724,3749,3767,3802,3824,3849,3874,3892,3916,3941,3967,3985,4008,4033,4061,4079,4101,4127,4150,4173,4200,4218,4243,4269,4296,4314,4332,4350,4376,4394,4412],{"intervention":96,"totalTrials":97,"cells":98},"Dexmedetomidine Hydrochloride Group",2,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":151},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[],{"trials":109,"activeCount":97,"soonestReadout":143},[110,138],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":137},"NCT04289142","Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients","RECRUITING",[92],"2028-07","2029-03","2019-12-01",2400,[120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136],"Delirium","Cognitive Dysfunction","Cognition Disorder","Neurocognitive Disorders","Mental Disorders","Confusion","Neurobehavioral Manifestations","Neurologic Manifestations","Nervous System Diseases","Signs and Symptoms","Dexmedetomidine","Hypnotics and Sedatives","Central Nervous System Depressants","Physiological Effects of Drugs","Analgesics, Non-Narcotic","Analgesics","Molecular Mechanisms of Pharmacological Action",[96],{"nctId":139,"briefTitle":140,"status":141,"phases":142,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":150},"NCT03480061","Dexmedetomidine to Reduce the Incidence of POCD After Open Cardiac Surgery","ACTIVE_NOT_RECRUITING",[92],"2026-07","2026-12","2018-08-09",90,[120,148,130,149,24],"Postoperative Cognitive Dysfunction","Cognitive Impairment",[96],{"trials":152,"activeCount":101},[],{"intervention":154,"totalTrials":155,"cells":156},"Glucocorticoid",1,{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":177},{"trials":158,"activeCount":101},[],{"trials":160,"activeCount":101},[],{"trials":162,"activeCount":101},[],{"trials":164,"activeCount":101},[],{"trials":166,"activeCount":155,"soonestReadout":116},[167],{"nctId":168,"briefTitle":169,"status":113,"phases":170,"primaryCompletion":116,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":176},"NCT07245732","Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares",[92],"2029-07","2026-04",220,[175],"Rheumatoid Arthritis (RA)",[154],{"trials":178,"activeCount":101},[],{"intervention":180,"totalTrials":181,"cells":182},"Duloxetine",3,{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":191,"NA":204},{"trials":184,"activeCount":101},[],{"trials":186,"activeCount":101},[],{"trials":188,"activeCount":101},[],{"trials":190,"activeCount":101},[],{"trials":192,"activeCount":155,"soonestReadout":197},[193],{"nctId":194,"briefTitle":195,"status":113,"phases":196,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":201,"interventions":203},"NCT06423716","Effect of peRiopErative duLoxetIne Administration on Opioid Consumption Following Total kneE Arthroplasty (RELIFE)",[92],"2026-07-01","2026-12-31","2024-11-01",150,[202],"Knee Osteoarthritis",[180],{"trials":205,"activeCount":101},[206,216],{"nctId":207,"briefTitle":208,"status":209,"phases":210,"primaryCompletion":211,"completion":212,"start":213,"enrollment":155,"conditions":214,"interventions":215},"NCT01650740","Study of Placebo Without Deception Versus Standard Antidepressant for Major Depressive Disorder","TERMINATED",[93],"2014-08","2014-11","2012-08",[33],[180],{"nctId":217,"briefTitle":218,"status":219,"phases":220,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":227},"NCT01404871","Predicting Medication Response in Obsessive Compulsive Disorder","COMPLETED",[93],"2011-10","2011-12","2009-04",26,[226],"Obsessive Compulsive Disorder",[228,229,230],"clomipramine","escitalopram","duloxetine",{"intervention":86,"totalTrials":97,"cells":232},{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":263,"NA":265},{"trials":234,"activeCount":101},[],{"trials":236,"activeCount":101},[],{"trials":238,"activeCount":101},[],{"trials":240,"activeCount":97,"soonestReadout":85},[241,251],{"nctId":83,"briefTitle":84,"status":141,"phases":242,"primaryCompletion":85,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":249},[91],"2027-06-15","2020-06-15",800,[247,248],"Covid19","Hypoxic Respiratory Failure",[86,250],"Sevoflurane inhalant product",{"nctId":252,"briefTitle":253,"status":113,"phases":254,"primaryCompletion":255,"completion":144,"start":256,"enrollment":257,"conditions":258,"interventions":262},"NCT05867472","Advancing Brain Outcomes in Pediatric Critically Ill Patients Sedated With Volatile AnEsthestic Agents",[91],"2026-05","2023-10-10",60,[259,260,261],"Intensive Care Units, Pediatric","Anesthetics, Inhalation","Mechanically Ventilated, Critically Ill Children",[86],{"trials":264,"activeCount":101},[],{"trials":266,"activeCount":101},[],{"intervention":42,"totalTrials":181,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":286,"PHASE4":309,"NA":311},{"trials":270,"activeCount":101},[],{"trials":272,"activeCount":101},[],{"trials":274,"activeCount":101},[275],{"nctId":276,"briefTitle":277,"status":219,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":285},"NCT05075200","Tranexamic Acid Dosing for Major Joint Replacement Surgery",[90],"2022-10-26","2021-12-14",21,[283,284],"Arthroplasty, Replacement, Knee","Arthroplasty, Replacement, Hip",[42],{"trials":287,"activeCount":155,"soonestReadout":41},[288,302],{"nctId":289,"briefTitle":290,"status":219,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":299},"NCT01651182","Tranexamic Acid Versus Placebo for Blood to Reduce Perioperative Bleeding Post-liver Resection",[91],"2015-02","2014-03",24,[296,297,298],"Cancer","Tumour","Surgery",[300,301],"No tranexamic acid","Tranexamic Acid",{"nctId":39,"briefTitle":40,"status":141,"phases":303,"primaryCompletion":41,"completion":304,"start":212,"enrollment":305,"conditions":306,"interventions":307},[91],"2027-08",1386,[296,297,298],[42,308],"Normal saline",{"trials":310,"activeCount":101},[],{"trials":312,"activeCount":101},[],{"intervention":308,"totalTrials":181,"cells":314},{"EARLY_PHASE1":315,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":352,"NA":354},{"trials":316,"activeCount":101},[317],{"nctId":318,"briefTitle":319,"status":219,"phases":320,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":327},"NCT02802696","Transfusion-Associated Circulatory Overload Best Eliminated With Lasix",[88],"2017-03-17","2017-04-15","2016-06",80,[326],"Transfusion-associated Circulatory Overload",[328,329],"Furosemide","Normal Saline",{"trials":331,"activeCount":101},[],{"trials":333,"activeCount":101},[],{"trials":335,"activeCount":155,"soonestReadout":41},[336,340],{"nctId":39,"briefTitle":40,"status":141,"phases":337,"primaryCompletion":41,"completion":304,"start":212,"enrollment":305,"conditions":338,"interventions":339},[91],[296,297,298],[42,308],{"nctId":341,"briefTitle":342,"status":219,"phases":343,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":350},"NCT03069183","Ultrasound-guided Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Total Hip Arthroplasty",[90,91],"2022-04-27","2022-05-01","2018-08-30",133,[349],"Arthritis of Hip",[351,308],"0.5% Ropivacaine",{"trials":353,"activeCount":101},[],{"trials":355,"activeCount":101},[],{"intervention":357,"totalTrials":97,"cells":358},"Ketamine",{"EARLY_PHASE1":359,"PHASE1":374,"PHASE2":376,"PHASE3":378,"PHASE4":390,"NA":392},{"trials":360,"activeCount":101},[361],{"nctId":362,"briefTitle":363,"status":219,"phases":364,"primaryCompletion":365,"completion":365,"start":366,"enrollment":36,"conditions":367,"interventions":372},"NCT02593643","Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.",[88],"2017-04","2016-01",[33,368,369,370,371],"Bipolar I Disorder","Bipolar II Disorder","Bipolar Depression","Suicidal Ideation",[357,373],"Midazolam",{"trials":375,"activeCount":101},[],{"trials":377,"activeCount":101},[],{"trials":379,"activeCount":155,"soonestReadout":385},[380],{"nctId":381,"briefTitle":382,"status":383,"phases":384,"primaryCompletion":385,"completion":385,"start":255,"enrollment":386,"conditions":387,"interventions":389},"NCT06781697","InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression","NOT_YET_RECRUITING",[91],"2027-12",31,[388],"Treatment Resistant Depression",[357],{"trials":391,"activeCount":101},[],{"trials":393,"activeCount":101},[],{"intervention":395,"totalTrials":97,"cells":396},"Nabilone",{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":428,"NA":430},{"trials":398,"activeCount":101},[],{"trials":400,"activeCount":101},[],{"trials":402,"activeCount":101},[],{"trials":404,"activeCount":155,"soonestReadout":423},[405,419],{"nctId":406,"briefTitle":407,"status":219,"phases":408,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":418},"NCT02351882","Safety and Efficacy of Nabilone in Alzheimer's Disease",[90,91],"2018-01","2019-03","2015-01",38,[30,414,415,416,417],"Agitation","Weight Loss","Pain","Oxidative Stress",[395],{"nctId":420,"briefTitle":421,"status":113,"phases":422,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":427},"NCT04516057","Nabilone for Agitation Blinded Intervention Trial",[91],"2027-04","2021-02-01",112,[30,414],[395],{"trials":429,"activeCount":101},[],{"trials":431,"activeCount":101},[],{"intervention":250,"totalTrials":155,"cells":433},{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":440,"PHASE4":446,"NA":448},{"trials":435,"activeCount":101},[],{"trials":437,"activeCount":101},[],{"trials":439,"activeCount":101},[],{"trials":441,"activeCount":155,"soonestReadout":85},[442],{"nctId":83,"briefTitle":84,"status":141,"phases":443,"primaryCompletion":85,"completion":243,"start":244,"enrollment":245,"conditions":444,"interventions":445},[91],[247,248],[86,250],{"trials":447,"activeCount":101},[],{"trials":449,"activeCount":101},[],{"intervention":451,"totalTrials":155,"cells":452},"modified PENTOCLO",{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":459,"PHASE4":472,"NA":474},{"trials":454,"activeCount":101},[],{"trials":456,"activeCount":101},[],{"trials":458,"activeCount":101},[],{"trials":460,"activeCount":155,"soonestReadout":385},[461],{"nctId":462,"briefTitle":463,"status":113,"phases":464,"primaryCompletion":385,"completion":385,"start":465,"enrollment":294,"conditions":466,"interventions":470},"NCT06055257","Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible",[91],"2025-01-16",[467,468,469],"Osteoradionecrosis","Osteoradionecrosis of Jaw","Osteoradionecrosis of the Mandible",[451,471],"sham mPENTOCLO",{"trials":473,"activeCount":101},[],{"trials":475,"activeCount":101},[],{"intervention":471,"totalTrials":155,"cells":477},{"EARLY_PHASE1":478,"PHASE1":480,"PHASE2":482,"PHASE3":484,"PHASE4":490,"NA":492},{"trials":479,"activeCount":101},[],{"trials":481,"activeCount":101},[],{"trials":483,"activeCount":101},[],{"trials":485,"activeCount":155,"soonestReadout":385},[486],{"nctId":462,"briefTitle":463,"status":113,"phases":487,"primaryCompletion":385,"completion":385,"start":465,"enrollment":294,"conditions":488,"interventions":489},[91],[467,468,469],[451,471],{"trials":491,"activeCount":101},[],{"trials":493,"activeCount":101},[],{"intervention":495,"totalTrials":155,"cells":496},"Dalteparin",{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":501,"PHASE3":503,"PHASE4":515,"NA":517},{"trials":498,"activeCount":101},[],{"trials":500,"activeCount":101},[],{"trials":502,"activeCount":101},[],{"trials":504,"activeCount":155,"soonestReadout":144},[505],{"nctId":506,"briefTitle":507,"status":113,"phases":508,"primaryCompletion":144,"completion":385,"start":509,"enrollment":510,"conditions":511,"interventions":513},"NCT03559114","PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)",[91],"2018-07-19",1100,[512],"Traumatic Brain Injury",[495,514],"Saline",{"trials":516,"activeCount":101},[],{"trials":518,"activeCount":101},[],{"intervention":514,"totalTrials":155,"cells":520},{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":533,"NA":535},{"trials":522,"activeCount":101},[],{"trials":524,"activeCount":101},[],{"trials":526,"activeCount":101},[],{"trials":528,"activeCount":155,"soonestReadout":144},[529],{"nctId":506,"briefTitle":507,"status":113,"phases":530,"primaryCompletion":144,"completion":385,"start":509,"enrollment":510,"conditions":531,"interventions":532},[91],[512],[495,514],{"trials":534,"activeCount":101},[],{"trials":536,"activeCount":101},[],{"intervention":538,"totalTrials":155,"cells":539},"Edoxaban 15 mg",{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":546,"PHASE4":558,"NA":560},{"trials":541,"activeCount":101},[],{"trials":543,"activeCount":101},[],{"trials":545,"activeCount":101},[],{"trials":547,"activeCount":155,"soonestReadout":552},[548],{"nctId":549,"briefTitle":550,"status":383,"phases":551,"primaryCompletion":552,"completion":552,"start":172,"enrollment":553,"conditions":554,"interventions":556},"NCT07454707","Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial",[91],"2031-12",1204,[555],"Stroke, Ischemic",[538,557],"Aspirin or clopidogrel",{"trials":559,"activeCount":101},[],{"trials":561,"activeCount":101},[],{"intervention":557,"totalTrials":155,"cells":563},{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":570,"PHASE4":576,"NA":578},{"trials":565,"activeCount":101},[],{"trials":567,"activeCount":101},[],{"trials":569,"activeCount":101},[],{"trials":571,"activeCount":155,"soonestReadout":552},[572],{"nctId":549,"briefTitle":550,"status":383,"phases":573,"primaryCompletion":552,"completion":552,"start":172,"enrollment":553,"conditions":574,"interventions":575},[91],[555],[538,557],{"trials":577,"activeCount":101},[],{"trials":579,"activeCount":101},[],{"intervention":581,"totalTrials":155,"cells":582},"Eptinezumab",{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":589,"PHASE4":601,"NA":603},{"trials":584,"activeCount":101},[],{"trials":586,"activeCount":101},[],{"trials":588,"activeCount":101},[],{"trials":590,"activeCount":155,"soonestReadout":595},[591],{"nctId":592,"briefTitle":593,"status":383,"phases":594,"primaryCompletion":595,"completion":596,"start":597,"enrollment":324,"conditions":598,"interventions":600},"NCT07191145","Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)",[91],"2027-06-30","2027-09-01","2026-01-01",[599],"Post Traumatic Headache",[581],{"trials":602,"activeCount":101},[],{"trials":604,"activeCount":101},[],{"intervention":57,"totalTrials":181,"cells":606},{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":630,"PHASE3":639,"PHASE4":641,"NA":643},{"trials":608,"activeCount":101},[],{"trials":610,"activeCount":155,"soonestReadout":56},[611,619],{"nctId":54,"briefTitle":55,"status":113,"phases":612,"primaryCompletion":56,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":618},[89],"2028-07-11","2022-06-15",20,[617],"Melanoma",[57],{"nctId":620,"briefTitle":621,"status":622,"phases":623,"primaryCompletion":624,"completion":624,"start":625,"enrollment":615,"conditions":626,"interventions":628},"NCT04431648","Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Head and Neck Cancer","UNKNOWN",[89],"2024-05-01","2020-05-01",[627],"Head and Neck Cancer",[629],"DEFINITY",{"trials":631,"activeCount":155,"soonestReadout":76},[632],{"nctId":74,"briefTitle":75,"status":113,"phases":633,"primaryCompletion":76,"completion":634,"start":635,"enrollment":636,"conditions":637,"interventions":638},[90],"2029-02-01","2024-07-25",200,[15],[57],{"trials":640,"activeCount":101},[],{"trials":642,"activeCount":101},[],{"trials":644,"activeCount":101},[],{"intervention":646,"totalTrials":181,"cells":647},"Methylphenidate",{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":652,"PHASE3":667,"PHASE4":669,"NA":682},{"trials":649,"activeCount":101},[],{"trials":651,"activeCount":101},[],{"trials":653,"activeCount":155,"soonestReadout":658},[654],{"nctId":655,"briefTitle":656,"status":113,"phases":657,"primaryCompletion":658,"completion":658,"start":659,"enrollment":25,"conditions":660,"interventions":666},"NCT07279740","Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia",[90],"2027-10-01","2026-01",[661,662,663,30,664,665],"Alzheimer s Disease","Alzheimer Dementia (AD)","Alzheimer Dementia","Apathy","Apathy in Dementia",[646],{"trials":668,"activeCount":101},[],{"trials":670,"activeCount":101},[671],{"nctId":672,"briefTitle":673,"status":219,"phases":674,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":680},"NCT00254033","Apathy Associated With Alzheimer's Disease",[92],"2006-10","2003-10",40,[679,30],"Dementia",[681,646],"Dextroamphetamine",{"trials":683,"activeCount":155,"soonestReadout":688},[684],{"nctId":685,"briefTitle":686,"status":113,"phases":687,"primaryCompletion":688,"completion":688,"start":689,"enrollment":31,"conditions":690,"interventions":693},"NCT05561205","rTMS for Apathy Clinical Trial",[93],"2026-12-01","2023-02-09",[30,665,679,691,692,123],"Mild Behavioural Impairment","Mild Cognitive Impairment",[694],"methylphenidate",{"intervention":696,"totalTrials":97,"cells":697},"Rituximab",{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":724,"PHASE4":726,"NA":728},{"trials":699,"activeCount":101},[],{"trials":701,"activeCount":101},[],{"trials":703,"activeCount":155,"soonestReadout":71},[704,713],{"nctId":69,"briefTitle":70,"status":141,"phases":705,"primaryCompletion":71,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":711},[90],"2030-03","2021-03-02",63,[710],"Waldenstrom Macroglobulinemia",[72,712,696],"Bendamustine",{"nctId":714,"briefTitle":715,"status":219,"phases":716,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":722},"NCT03069248","Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon",[90],"2009-09-17","2000-06-01",36,[721],"Follicular Lymphoma",[696,723],"Alpha Interferon",{"trials":725,"activeCount":101},[],{"trials":727,"activeCount":101},[],{"trials":729,"activeCount":101},[],{"intervention":731,"totalTrials":155,"cells":732},"Sodium Thiosulfate + Mannitol",{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":749,"PHASE4":751,"NA":753},{"trials":734,"activeCount":101},[],{"trials":736,"activeCount":101},[],{"trials":738,"activeCount":155,"soonestReadout":743},[739],{"nctId":740,"briefTitle":741,"status":113,"phases":742,"primaryCompletion":743,"completion":385,"start":744,"enrollment":745,"conditions":746,"interventions":748},"NCT05129748","Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy",[90],"2027-01","2023-02-15",92,[747],"Ototoxic Hearing Loss",[731],{"trials":750,"activeCount":101},[],{"trials":752,"activeCount":101},[],{"trials":754,"activeCount":101},[],{"intervention":756,"totalTrials":155,"cells":757},"Enzalutamide Dose Escalation",{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":762,"PHASE3":775,"PHASE4":777,"NA":779},{"trials":759,"activeCount":101},[],{"trials":761,"activeCount":101},[],{"trials":763,"activeCount":155,"soonestReadout":768},[764],{"nctId":765,"briefTitle":766,"status":383,"phases":767,"primaryCompletion":768,"completion":385,"start":172,"enrollment":224,"conditions":769,"interventions":773},"NCT07512076","A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer",[90],"2027-07",[770,771,772],"Prostate Cancer Patients","Elderly Patients","Pharmacokinetic Study",[756,774],"Standard of Care",{"trials":776,"activeCount":101},[],{"trials":778,"activeCount":101},[],{"trials":780,"activeCount":101},[],{"intervention":774,"totalTrials":155,"cells":782},{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":784,"activeCount":101},[],{"trials":786,"activeCount":101},[],{"trials":788,"activeCount":155,"soonestReadout":768},[789],{"nctId":765,"briefTitle":766,"status":383,"phases":790,"primaryCompletion":768,"completion":385,"start":172,"enrollment":224,"conditions":791,"interventions":792},[90],[770,771,772],[756,774],{"trials":794,"activeCount":101},[],{"trials":796,"activeCount":101},[],{"trials":798,"activeCount":101},[],{"intervention":800,"totalTrials":155,"cells":801},"Levetiracetam",{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":818,"PHASE4":820,"NA":822},{"trials":803,"activeCount":101},[],{"trials":805,"activeCount":101},[],{"trials":807,"activeCount":155,"soonestReadout":743},[808],{"nctId":809,"briefTitle":810,"status":113,"phases":811,"primaryCompletion":743,"completion":812,"start":813,"enrollment":677,"conditions":814,"interventions":817},"NCT07477431","Levetiracetam for Persons at Risk for Alzheimer's Disease",[90],"2027-02","2025-10-23",[815,816],"Hippocampal Hyperactivation","Prodromal Alzheimer Disease",[800],{"trials":819,"activeCount":101},[],{"trials":821,"activeCount":101},[],{"trials":823,"activeCount":101},[],{"intervention":825,"totalTrials":155,"cells":826},"QBECO",{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":844,"PHASE4":846,"NA":848},{"trials":828,"activeCount":101},[],{"trials":830,"activeCount":101},[],{"trials":832,"activeCount":155,"soonestReadout":812},[833],{"nctId":834,"briefTitle":835,"status":141,"phases":836,"primaryCompletion":812,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":843},"NCT05677113","A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver",[90],"2031-02-01","2023-08-01",115,[841,842],"Colorectal Cancer","Liver Metastases",[825],{"trials":845,"activeCount":101},[],{"trials":847,"activeCount":101},[],{"trials":849,"activeCount":101},[],{"intervention":72,"totalTrials":155,"cells":851},{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":862,"PHASE4":864,"NA":866},{"trials":853,"activeCount":101},[],{"trials":855,"activeCount":101},[],{"trials":857,"activeCount":155,"soonestReadout":71},[858],{"nctId":69,"briefTitle":70,"status":141,"phases":859,"primaryCompletion":71,"completion":706,"start":707,"enrollment":708,"conditions":860,"interventions":861},[90],[710],[72,712,696],{"trials":863,"activeCount":101},[],{"trials":865,"activeCount":101},[],{"trials":867,"activeCount":101},[],{"intervention":712,"totalTrials":155,"cells":869},{"EARLY_PHASE1":870,"PHASE1":872,"PHASE2":874,"PHASE3":880,"PHASE4":882,"NA":884},{"trials":871,"activeCount":101},[],{"trials":873,"activeCount":101},[],{"trials":875,"activeCount":155,"soonestReadout":71},[876],{"nctId":69,"briefTitle":70,"status":141,"phases":877,"primaryCompletion":71,"completion":706,"start":707,"enrollment":708,"conditions":878,"interventions":879},[90],[710],[72,712,696],{"trials":881,"activeCount":101},[],{"trials":883,"activeCount":101},[],{"trials":885,"activeCount":101},[],{"intervention":887,"totalTrials":155,"cells":888},"CBD",{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":903,"PHASE4":905,"NA":907},{"trials":890,"activeCount":101},[],{"trials":892,"activeCount":101},[],{"trials":894,"activeCount":155,"soonestReadout":899},[895],{"nctId":896,"briefTitle":897,"status":113,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":677,"conditions":901,"interventions":902},"NCT06014424","Cannabidiol Medication Intervention Trial",[90],"2026-12-29","2023-09-27",[30],[887],{"trials":904,"activeCount":101},[],{"trials":906,"activeCount":101},[],{"trials":908,"activeCount":101},[],{"intervention":67,"totalTrials":155,"cells":910},{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":912,"activeCount":101},[],{"trials":914,"activeCount":101},[],{"trials":916,"activeCount":155,"soonestReadout":66},[917],{"nctId":64,"briefTitle":65,"status":141,"phases":918,"primaryCompletion":66,"completion":919,"start":920,"enrollment":257,"conditions":921,"interventions":922},[89,90],"2027-10","2020-10-27",[18],[67],{"trials":924,"activeCount":101},[],{"trials":926,"activeCount":101},[],{"trials":928,"activeCount":101},[],{"intervention":930,"totalTrials":155,"cells":931},"Daily TMZ",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":948,"PHASE4":950,"NA":952},{"trials":933,"activeCount":101},[],{"trials":935,"activeCount":101},[],{"trials":937,"activeCount":155,"soonestReadout":919},[938],{"nctId":939,"briefTitle":940,"status":113,"phases":941,"primaryCompletion":919,"completion":942,"start":943,"enrollment":944,"conditions":945,"interventions":947},"NCT07476794","Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma",[90],"2029-11","2025-11-01",118,[946],"Glioblastoma",[930],{"trials":949,"activeCount":101},[],{"trials":951,"activeCount":101},[],{"trials":953,"activeCount":101},[],{"intervention":955,"totalTrials":155,"cells":956},"Psilocybin",{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":973,"PHASE4":975,"NA":977},{"trials":958,"activeCount":101},[],{"trials":960,"activeCount":101},[],{"trials":962,"activeCount":155,"soonestReadout":967},[963],{"nctId":964,"briefTitle":965,"status":113,"phases":966,"primaryCompletion":967,"completion":968,"start":969,"enrollment":11,"conditions":970,"interventions":972},"NCT06072898","A Randomized Neuroimaging Trial of Psilocybin in Depression",[90],"2028-05","2029-05","2025-05-28",[971,33],"Depressive Disorder",[955],{"trials":974,"activeCount":101},[],{"trials":976,"activeCount":101},[],{"trials":978,"activeCount":101},[],{"intervention":980,"totalTrials":155,"cells":981},"Tucatinib 150 MG",{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":1000,"PHASE4":1002,"NA":1004},{"trials":983,"activeCount":101},[],{"trials":985,"activeCount":101},[],{"trials":987,"activeCount":155,"soonestReadout":198},[988],{"nctId":989,"briefTitle":990,"status":113,"phases":991,"primaryCompletion":198,"completion":992,"start":993,"enrollment":16,"conditions":994,"interventions":997},"NCT06016387","Tucatinib, Trastuzumab and Capecitabine With Brain and\u002For Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and\u002For HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study",[90],"2028-10-05","2023-11-25",[995,996],"HER2-positive Breast Cancer","LMD",[980,998,999],"Trastuzumab","Capecitabine",{"trials":1001,"activeCount":101},[],{"trials":1003,"activeCount":101},[],{"trials":1005,"activeCount":101},[],{"intervention":998,"totalTrials":155,"cells":1007},{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1018,"PHASE4":1020,"NA":1022},{"trials":1009,"activeCount":101},[],{"trials":1011,"activeCount":101},[],{"trials":1013,"activeCount":155,"soonestReadout":198},[1014],{"nctId":989,"briefTitle":990,"status":113,"phases":1015,"primaryCompletion":198,"completion":992,"start":993,"enrollment":16,"conditions":1016,"interventions":1017},[90],[995,996],[980,998,999],{"trials":1019,"activeCount":101},[],{"trials":1021,"activeCount":101},[],{"trials":1023,"activeCount":101},[],{"intervention":999,"totalTrials":155,"cells":1025},{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1030,"PHASE3":1036,"PHASE4":1038,"NA":1040},{"trials":1027,"activeCount":101},[],{"trials":1029,"activeCount":101},[],{"trials":1031,"activeCount":155,"soonestReadout":198},[1032],{"nctId":989,"briefTitle":990,"status":113,"phases":1033,"primaryCompletion":198,"completion":992,"start":993,"enrollment":16,"conditions":1034,"interventions":1035},[90],[995,996],[980,998,999],{"trials":1037,"activeCount":101},[],{"trials":1039,"activeCount":101},[],{"trials":1041,"activeCount":101},[],{"intervention":62,"totalTrials":155,"cells":1043},{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1048,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1045,"activeCount":101},[],{"trials":1047,"activeCount":101},[],{"trials":1049,"activeCount":155,"soonestReadout":61},[1050],{"nctId":59,"briefTitle":60,"status":113,"phases":1051,"primaryCompletion":61,"completion":1052,"start":1053,"enrollment":677,"conditions":1054,"interventions":1059},[90],"2027-09","2023-08-21",[1055,1056,1057,1058],"Ovarian Cancer","Stage III Ovarian Cancer","Stage IV Ovarian Cancer","High Grade Ovarian Serous Adenocarcinoma",[62],{"trials":1061,"activeCount":101},[],{"trials":1063,"activeCount":101},[],{"trials":1065,"activeCount":101},[],{"intervention":1067,"totalTrials":97,"cells":1068},"Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension",{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1102,"PHASE3":1104,"PHASE4":1106,"NA":1108},{"trials":1070,"activeCount":101},[],{"trials":1072,"activeCount":97,"soonestReadout":1093},[1073,1089],{"nctId":1074,"briefTitle":1075,"status":113,"phases":1076,"primaryCompletion":768,"completion":1077,"start":1078,"enrollment":31,"conditions":1079,"interventions":1088},"NCT07179328","Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy",[89],"2027-11","2025-06-04",[1080,1081,1082,1083,1084,1085,1086,1087],"GBM","Glioblastoma Multiforme (GBM)","Glioblastoma Multiforme of Brain","Glioblastoma Multiforme Glioma","HGG","Glioma","Brain Tumor Adult","Brain Tumor, Primary",[1067],{"nctId":1090,"briefTitle":1091,"status":113,"phases":1092,"primaryCompletion":1093,"completion":1094,"start":1095,"enrollment":1096,"conditions":1097,"interventions":1100},"NCT07193953","Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)",[89],"2026-11-30","2027-05-30","2025-04-15",6,[1098,1099],"Amyotrophic Lateral Sclerosis","ALS",[1101,1067],"Intravenous immunoglobulin (IVIG), 10% solution for",{"trials":1103,"activeCount":101},[],{"trials":1105,"activeCount":101},[],{"trials":1107,"activeCount":101},[],{"trials":1109,"activeCount":101},[],{"intervention":81,"totalTrials":97,"cells":1111},{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1130,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1113,"activeCount":101},[],{"trials":1115,"activeCount":155,"soonestReadout":80},[1116,1122],{"nctId":78,"briefTitle":79,"status":113,"phases":1117,"primaryCompletion":80,"completion":1118,"start":1119,"enrollment":16,"conditions":1120,"interventions":1121},[89],"2029-03-01","2024-07-01",[15],[81],{"nctId":1123,"briefTitle":1124,"status":219,"phases":1125,"primaryCompletion":1126,"completion":1126,"start":1127,"enrollment":615,"conditions":1128,"interventions":1129},"NCT04431674","Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Chest-wall and Breast Cancer",[89],"2023-06-21","2020-07-22",[15],[81],{"trials":1131,"activeCount":101},[],{"trials":1133,"activeCount":101},[],{"trials":1135,"activeCount":101},[],{"trials":1137,"activeCount":101},[],{"intervention":1139,"totalTrials":97,"cells":1140},"Hyperpolarized 13C-Pyruvate",{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1165,"PHASE3":1167,"PHASE4":1169,"NA":1171},{"trials":1142,"activeCount":101},[],{"trials":1144,"activeCount":155,"soonestReadout":743},[1145,1154],{"nctId":1146,"briefTitle":1147,"status":113,"phases":1148,"primaryCompletion":743,"completion":743,"start":1149,"enrollment":1150,"conditions":1151,"interventions":1153},"NCT03324360","Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)",[89],"2017-12-06",276,[1152],"Brain Metastases",[1139],{"nctId":1155,"briefTitle":1156,"status":209,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":1161,"interventions":1163},"NCT03129776","Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer",[89],"2022-09-15","2017-11-13",4,[1162],"Uterine Cervical Neoplasms",[1139,1164],"18F-FDG",{"trials":1166,"activeCount":101},[],{"trials":1168,"activeCount":101},[],{"trials":1170,"activeCount":101},[],{"trials":1172,"activeCount":101},[],{"intervention":52,"totalTrials":155,"cells":1174},{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1188,"PHASE3":1190,"PHASE4":1192,"NA":1194},{"trials":1176,"activeCount":101},[],{"trials":1178,"activeCount":155,"soonestReadout":51},[1179],{"nctId":49,"briefTitle":50,"status":141,"phases":1180,"primaryCompletion":51,"completion":1181,"start":1182,"enrollment":719,"conditions":1183,"interventions":1186},[89],"2025-04-28","2022-11-09",[1184,1185,1055],"High Grade Serous Carcinoma","Triple Negative Breast Cancer",[52,1187],"Navitoclax",{"trials":1189,"activeCount":101},[],{"trials":1191,"activeCount":101},[],{"trials":1193,"activeCount":101},[],{"trials":1195,"activeCount":101},[],{"intervention":1187,"totalTrials":155,"cells":1197},{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1206,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1199,"activeCount":101},[],{"trials":1201,"activeCount":155,"soonestReadout":51},[1202],{"nctId":49,"briefTitle":50,"status":141,"phases":1203,"primaryCompletion":51,"completion":1181,"start":1182,"enrollment":719,"conditions":1204,"interventions":1205},[89],[1184,1185,1055],[52,1187],{"trials":1207,"activeCount":101},[],{"trials":1209,"activeCount":101},[],{"trials":1211,"activeCount":101},[],{"trials":1213,"activeCount":101},[],{"intervention":1101,"totalTrials":155,"cells":1215},{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1224,"PHASE3":1226,"PHASE4":1228,"NA":1230},{"trials":1217,"activeCount":101},[],{"trials":1219,"activeCount":155,"soonestReadout":1093},[1220],{"nctId":1090,"briefTitle":1091,"status":113,"phases":1221,"primaryCompletion":1093,"completion":1094,"start":1095,"enrollment":1096,"conditions":1222,"interventions":1223},[89],[1098,1099],[1101,1067],{"trials":1225,"activeCount":101},[],{"trials":1227,"activeCount":101},[],{"trials":1229,"activeCount":101},[],{"trials":1231,"activeCount":101},[],{"intervention":1233,"totalTrials":155,"cells":1234},"Hyperpolarized (13) Pyruvate",{"EARLY_PHASE1":1235,"PHASE1":1237,"PHASE2":1248,"PHASE3":1250,"PHASE4":1252,"NA":1254},{"trials":1236,"activeCount":101},[],{"trials":1238,"activeCount":155,"soonestReadout":423},[1239],{"nctId":1240,"briefTitle":1241,"status":113,"phases":1242,"primaryCompletion":423,"completion":423,"start":1243,"enrollment":425,"conditions":1244,"interventions":1246},"NCT02648009","Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection",[89],"2016-04",[27,1245],"Hypertrophy",[1233,1247],"Gadolinium",{"trials":1249,"activeCount":101},[],{"trials":1251,"activeCount":101},[],{"trials":1253,"activeCount":101},[],{"trials":1255,"activeCount":101},[],{"intervention":1247,"totalTrials":155,"cells":1257},{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1266,"PHASE3":1268,"PHASE4":1270,"NA":1272},{"trials":1259,"activeCount":101},[],{"trials":1261,"activeCount":155,"soonestReadout":423},[1262],{"nctId":1240,"briefTitle":1241,"status":113,"phases":1263,"primaryCompletion":423,"completion":423,"start":1243,"enrollment":425,"conditions":1264,"interventions":1265},[89],[27,1245],[1233,1247],{"trials":1267,"activeCount":101},[],{"trials":1269,"activeCount":101},[],{"trials":1271,"activeCount":101},[],{"trials":1273,"activeCount":101},[],{"intervention":1275,"totalTrials":155,"cells":1276},"CPAP Therapy Combined with Web-Based Sleep Education for Cognitive and Sleep Health",{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1281,"PHASE3":1283,"PHASE4":1285,"NA":1287},{"trials":1278,"activeCount":101},[],{"trials":1280,"activeCount":101},[],{"trials":1282,"activeCount":101},[],{"trials":1284,"activeCount":101},[],{"trials":1286,"activeCount":101},[],{"trials":1288,"activeCount":155,"soonestReadout":1052},[1289],{"nctId":1290,"briefTitle":1291,"status":383,"phases":1292,"primaryCompletion":1052,"completion":1293,"start":1294,"enrollment":1295,"conditions":1296,"interventions":1300},"NCT06773416","CPAP Randomized Controlled Trial",[93],"2028-01","2025-02",206,[1297,1298,1299],"Obstructive Sleep Apnea (OSA)","Mild Cognitive Impairment (MCI)","Cognitive Decline Prevention in Pre-frail Older Adults",[1275,1301],"Delayed CPAP Therapy Combined with Web-Based Sleep Education for Cognitive and Sleep Health",{"intervention":1301,"totalTrials":155,"cells":1303},{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1310,"PHASE4":1312,"NA":1314},{"trials":1305,"activeCount":101},[],{"trials":1307,"activeCount":101},[],{"trials":1309,"activeCount":101},[],{"trials":1311,"activeCount":101},[],{"trials":1313,"activeCount":101},[],{"trials":1315,"activeCount":155,"soonestReadout":1052},[1316],{"nctId":1290,"briefTitle":1291,"status":383,"phases":1317,"primaryCompletion":1052,"completion":1293,"start":1294,"enrollment":1295,"conditions":1318,"interventions":1319},[93],[1297,1298,1299],[1275,1301],{"intervention":1321,"totalTrials":155,"cells":1322},"Cannabis oil",{"EARLY_PHASE1":1323,"PHASE1":1325,"PHASE2":1327,"PHASE3":1329,"PHASE4":1331,"NA":1333},{"trials":1324,"activeCount":101},[],{"trials":1326,"activeCount":101},[],{"trials":1328,"activeCount":101},[],{"trials":1330,"activeCount":101},[],{"trials":1332,"activeCount":101},[],{"trials":1334,"activeCount":155,"soonestReadout":144},[1335],{"nctId":1336,"briefTitle":1337,"status":113,"phases":1338,"primaryCompletion":144,"completion":1339,"start":1340,"enrollment":16,"conditions":1341,"interventions":1343},"NCT06863740","Using Cannabis to Treat Restless Legs Syndrome",[93],"2027-05","2025-07-25",[1342],"Restless Leg Syndrome (RLS)",[1321,1344],"Cannabis placebo",{"intervention":1344,"totalTrials":155,"cells":1346},{"EARLY_PHASE1":1347,"PHASE1":1349,"PHASE2":1351,"PHASE3":1353,"PHASE4":1355,"NA":1357},{"trials":1348,"activeCount":101},[],{"trials":1350,"activeCount":101},[],{"trials":1352,"activeCount":101},[],{"trials":1354,"activeCount":101},[],{"trials":1356,"activeCount":101},[],{"trials":1358,"activeCount":155,"soonestReadout":144},[1359],{"nctId":1336,"briefTitle":1337,"status":113,"phases":1360,"primaryCompletion":144,"completion":1339,"start":1340,"enrollment":16,"conditions":1361,"interventions":1362},[93],[1342],[1321,1344],{"intervention":1364,"totalTrials":155,"cells":1365},"Point-of-Care CYP2C19 Testing",{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1372,"PHASE4":1374,"NA":1376},{"trials":1367,"activeCount":101},[],{"trials":1369,"activeCount":101},[],{"trials":1371,"activeCount":101},[],{"trials":1373,"activeCount":101},[],{"trials":1375,"activeCount":101},[],{"trials":1377,"activeCount":155,"soonestReadout":304},[1378],{"nctId":1379,"briefTitle":1380,"status":113,"phases":1381,"primaryCompletion":304,"completion":304,"start":1382,"enrollment":1383,"conditions":1384,"interventions":1386},"NCT06714526","Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD",[93],"2025-10-07",100,[1385],"Intracranial Atherosclerosis",[1364,1387,1388],"ticagrelor + aspirin","clopidogrel + aspirin",{"intervention":1387,"totalTrials":155,"cells":1390},{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1397,"PHASE4":1399,"NA":1401},{"trials":1392,"activeCount":101},[],{"trials":1394,"activeCount":101},[],{"trials":1396,"activeCount":101},[],{"trials":1398,"activeCount":101},[],{"trials":1400,"activeCount":101},[],{"trials":1402,"activeCount":155,"soonestReadout":304},[1403],{"nctId":1379,"briefTitle":1380,"status":113,"phases":1404,"primaryCompletion":304,"completion":304,"start":1382,"enrollment":1383,"conditions":1405,"interventions":1406},[93],[1385],[1364,1387,1388],{"intervention":1388,"totalTrials":155,"cells":1408},{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1415,"PHASE4":1417,"NA":1419},{"trials":1410,"activeCount":101},[],{"trials":1412,"activeCount":101},[],{"trials":1414,"activeCount":101},[],{"trials":1416,"activeCount":101},[],{"trials":1418,"activeCount":101},[],{"trials":1420,"activeCount":155,"soonestReadout":304},[1421],{"nctId":1379,"briefTitle":1380,"status":113,"phases":1422,"primaryCompletion":304,"completion":304,"start":1382,"enrollment":1383,"conditions":1423,"interventions":1424},[93],[1385],[1364,1387,1388],{"intervention":47,"totalTrials":155,"cells":1426},{"EARLY_PHASE1":1427,"PHASE1":1429,"PHASE2":1431,"PHASE3":1433,"PHASE4":1435,"NA":1437},{"trials":1428,"activeCount":101},[],{"trials":1430,"activeCount":101},[],{"trials":1432,"activeCount":101},[],{"trials":1434,"activeCount":101},[],{"trials":1436,"activeCount":101},[],{"trials":1438,"activeCount":155,"soonestReadout":46},[1439],{"nctId":44,"briefTitle":45,"status":141,"phases":1440,"primaryCompletion":46,"completion":1441,"start":1442,"enrollment":1443,"conditions":1444,"interventions":1446},[93],"2027-08-31","2023-01-06",166,[1445],"Pancreatic Insufficiency",[47],{"intervention":1448,"totalTrials":1160,"cells":1449},"Citalopram",{"EARLY_PHASE1":1450,"PHASE1":1452,"PHASE2":1454,"PHASE3":1456,"PHASE4":1468,"NA":1501},{"trials":1451,"activeCount":101},[],{"trials":1453,"activeCount":101},[],{"trials":1455,"activeCount":101},[],{"trials":1457,"activeCount":101},[1458],{"nctId":1459,"briefTitle":1460,"status":1461,"phases":1462,"completion":1463,"start":1464,"enrollment":257,"conditions":1465,"interventions":1467},"NCT00249886","Discontinuation Study Of Citalopram (Antidepressant) in Depressed Adolescents","WITHDRAWN",[91],"2006-11","2002-09",[1466],"Major Depression",[1448],{"trials":1469,"activeCount":101},[1470,1480,1490],{"nctId":1471,"briefTitle":1472,"status":219,"phases":1473,"primaryCompletion":1474,"completion":1475,"start":1476,"enrollment":636,"conditions":1477,"interventions":1478},"NCT00254007","Depression and Traumatic Brain Injury",[92],"2005-12","2010-05","2003-07",[24,512],[1479],"citalopram",{"nctId":1481,"briefTitle":1482,"status":219,"phases":1483,"primaryCompletion":1484,"completion":1485,"start":1486,"enrollment":1487,"conditions":1488,"interventions":1489},"NCT00254020","The Role of Cytokine-Serotonin Interactions in Post-Stroke Depression",[92],"2011-01","2013-12","2005-06",138,[24],[1448],{"nctId":1491,"briefTitle":1492,"status":219,"phases":1493,"primaryCompletion":1494,"completion":1495,"start":1496,"enrollment":1497,"conditions":1498,"interventions":1500},"NCT00376051","Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia",[92],"2009-07","2009-09","2006-09",22,[1499],"Frontotemporal Dementia",[1448],{"trials":1502,"activeCount":101},[],{"intervention":1504,"totalTrials":155,"cells":1505},"Triamcinolone Acetonide 1 ml of 40 mg\u002FmL suspension",{"EARLY_PHASE1":1506,"PHASE1":1508,"PHASE2":1510,"PHASE3":1512,"PHASE4":1514,"NA":1527},{"trials":1507,"activeCount":101},[],{"trials":1509,"activeCount":101},[],{"trials":1511,"activeCount":101},[],{"trials":1513,"activeCount":101},[],{"trials":1515,"activeCount":101},[1516],{"nctId":1517,"briefTitle":1518,"status":622,"phases":1519,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":615,"conditions":1523,"interventions":1526},"NCT02917564","Triamcinolone Injections for Persistent Choroidal Effusions Post Glaucoma Surgery",[92],"2023-05-31","2024-12-31","2020-10-14",[1524,1525],"Glaucoma","Choroidal Effusions",[1504],{"trials":1528,"activeCount":101},[],{"intervention":1530,"totalTrials":155,"cells":1531},"Pregabalin",{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1538,"PHASE4":1540,"NA":1551},{"trials":1533,"activeCount":101},[],{"trials":1535,"activeCount":101},[],{"trials":1537,"activeCount":101},[],{"trials":1539,"activeCount":101},[],{"trials":1541,"activeCount":101},[1542],{"nctId":1543,"briefTitle":1544,"status":622,"phases":1545,"primaryCompletion":222,"completion":222,"start":1546,"enrollment":1547,"conditions":1548,"interventions":1550},"NCT00762099","Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery",[92],"2009-05",184,[1549],"Anxiety",[1530],{"trials":1552,"activeCount":101},[],{"intervention":1554,"totalTrials":155,"cells":1555},"Sertraline",{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1562,"PHASE4":1564,"NA":1574},{"trials":1557,"activeCount":101},[],{"trials":1559,"activeCount":101},[],{"trials":1561,"activeCount":101},[],{"trials":1563,"activeCount":101},[],{"trials":1565,"activeCount":101},[1566],{"nctId":1567,"briefTitle":1568,"status":219,"phases":1569,"start":1570,"enrollment":1571,"conditions":1572,"interventions":1573},"NCT00508859","Maintenance Study for Adolescent Depression",[92],"1997-07",93,[24],[1554],{"trials":1575,"activeCount":101},[],{"intervention":1577,"totalTrials":155,"cells":1578},"Methoxyflurane, MEOF",{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1583,"PHASE3":1585,"PHASE4":1587,"NA":1599},{"trials":1580,"activeCount":101},[],{"trials":1582,"activeCount":101},[],{"trials":1584,"activeCount":101},[],{"trials":1586,"activeCount":101},[],{"trials":1588,"activeCount":101},[1589],{"nctId":1590,"briefTitle":1591,"status":622,"phases":1592,"primaryCompletion":1593,"completion":1594,"start":1595,"enrollment":31,"conditions":1596,"interventions":1598},"NCT04412642","Low Dose Methoxyflurane for Pain Relief During Minor Out-patient Urologic Procedures",[92],"2020-09-30","2020-12-31","2020-05-31",[1597],"Pain, Acute",[1577],{"trials":1600,"activeCount":101},[],{"intervention":1602,"totalTrials":155,"cells":1603},"Low Molecular Weight Heparin",{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1610,"PHASE4":1612,"NA":1625},{"trials":1605,"activeCount":101},[],{"trials":1607,"activeCount":101},[],{"trials":1609,"activeCount":101},[],{"trials":1611,"activeCount":101},[],{"trials":1613,"activeCount":101},[1614],{"nctId":1615,"briefTitle":1616,"status":219,"phases":1617,"completion":1618,"start":1619,"enrollment":1620,"conditions":1621,"interventions":1624},"NCT00187408","The D-KAF (Dalteparin in Knee-to-Ankle Fracture) Trial",[92],"2007-01","2002-08",700,[1622,1623],"Deep Vein Thrombosis","Pulmonary Embolism",[1602],{"trials":1626,"activeCount":101},[],{"intervention":1628,"totalTrials":155,"cells":1629},"donepezil",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1636,"PHASE4":1638,"NA":1650},{"trials":1631,"activeCount":101},[],{"trials":1633,"activeCount":101},[],{"trials":1635,"activeCount":101},[],{"trials":1637,"activeCount":101},[],{"trials":1639,"activeCount":101},[1640],{"nctId":1641,"briefTitle":1642,"status":219,"phases":1643,"primaryCompletion":1644,"completion":1644,"start":1645,"enrollment":1497,"conditions":1646,"interventions":1649},"NCT00482001","Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults",[92],"2008-08","2007-06",[1647,1648],"Mental Health","Geriatrics",[1628],{"trials":1651,"activeCount":101},[],{"intervention":1653,"totalTrials":155,"cells":1654},"aflibercept",{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1659,"PHASE3":1661,"PHASE4":1663,"NA":1676},{"trials":1656,"activeCount":101},[],{"trials":1658,"activeCount":101},[],{"trials":1660,"activeCount":101},[],{"trials":1662,"activeCount":101},[],{"trials":1664,"activeCount":101},[1665],{"nctId":1666,"briefTitle":1667,"status":622,"phases":1668,"primaryCompletion":1669,"completion":1669,"start":1670,"enrollment":146,"conditions":1671,"interventions":1675},"NCT02681783","PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept",[92],"2022-12-01","2018-12-01",[1672,1673,1674],"Central Serous Chorioretinopathy","Age Related Macular Degeneration","Idiopathic Poplypoidal Choroidal Vasculopathy",[1653],{"trials":1677,"activeCount":101},[],{"intervention":1679,"totalTrials":155,"cells":1680},"Bevacizumab",{"EARLY_PHASE1":1681,"PHASE1":1683,"PHASE2":1685,"PHASE3":1687,"PHASE4":1689,"NA":1703},{"trials":1682,"activeCount":101},[],{"trials":1684,"activeCount":101},[],{"trials":1686,"activeCount":101},[],{"trials":1688,"activeCount":101},[],{"trials":1690,"activeCount":101},[1691],{"nctId":1692,"briefTitle":1693,"status":219,"phases":1694,"primaryCompletion":1695,"completion":1485,"start":1696,"enrollment":1697,"conditions":1698,"interventions":1701},"NCT01166594","Use of Bevacizumab in Trabeculectomy Surgery",[92],"2013-09","2010-06",59,[1524,1699,1700],"Optic Neuropathy","Fibrosis",[1679,1702],"Control",{"trials":1704,"activeCount":101},[],{"intervention":1702,"totalTrials":155,"cells":1706},{"EARLY_PHASE1":1707,"PHASE1":1709,"PHASE2":1711,"PHASE3":1713,"PHASE4":1715,"NA":1721},{"trials":1708,"activeCount":101},[],{"trials":1710,"activeCount":101},[],{"trials":1712,"activeCount":101},[],{"trials":1714,"activeCount":101},[],{"trials":1716,"activeCount":101},[1717],{"nctId":1692,"briefTitle":1693,"status":219,"phases":1718,"primaryCompletion":1695,"completion":1485,"start":1696,"enrollment":1697,"conditions":1719,"interventions":1720},[92],[1524,1699,1700],[1679,1702],{"trials":1722,"activeCount":101},[],{"intervention":1724,"totalTrials":155,"cells":1725},"tinzaparin",{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1730,"PHASE3":1732,"PHASE4":1734,"NA":1746},{"trials":1727,"activeCount":101},[],{"trials":1729,"activeCount":101},[],{"trials":1731,"activeCount":101},[],{"trials":1733,"activeCount":101},[],{"trials":1735,"activeCount":101},[1736],{"nctId":1737,"briefTitle":1738,"status":209,"phases":1739,"primaryCompletion":1740,"completion":1740,"start":1741,"enrollment":36,"conditions":1742,"interventions":1744},"NCT04794569","Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome",[92],"2024-01-19","2021-11-15",[1622,1743],"Post Thrombotic Syndrome",[1724,1745],"Rivaroxaban",{"trials":1747,"activeCount":101},[],{"intervention":1745,"totalTrials":155,"cells":1749},{"EARLY_PHASE1":1750,"PHASE1":1752,"PHASE2":1754,"PHASE3":1756,"PHASE4":1758,"NA":1764},{"trials":1751,"activeCount":101},[],{"trials":1753,"activeCount":101},[],{"trials":1755,"activeCount":101},[],{"trials":1757,"activeCount":101},[],{"trials":1759,"activeCount":101},[1760],{"nctId":1737,"briefTitle":1738,"status":209,"phases":1761,"primaryCompletion":1740,"completion":1740,"start":1741,"enrollment":36,"conditions":1762,"interventions":1763},[92],[1622,1743],[1724,1745],{"trials":1765,"activeCount":101},[],{"intervention":1767,"totalTrials":155,"cells":1768},"Quetiapine (Seroquel) XR",{"EARLY_PHASE1":1769,"PHASE1":1771,"PHASE2":1773,"PHASE3":1775,"PHASE4":1777,"NA":1787},{"trials":1770,"activeCount":101},[],{"trials":1772,"activeCount":101},[],{"trials":1774,"activeCount":101},[],{"trials":1776,"activeCount":101},[],{"trials":1778,"activeCount":101},[1779],{"nctId":1780,"briefTitle":1781,"status":219,"phases":1782,"primaryCompletion":1783,"completion":1783,"start":1546,"enrollment":224,"conditions":1784,"interventions":1786},"NCT00892463","Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder",[92],"2010-12",[1785],"Depressive Disorder, Major",[1767],{"trials":1788,"activeCount":101},[],{"intervention":1790,"totalTrials":155,"cells":1791},"memantine",{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1796,"PHASE3":1798,"PHASE4":1800,"NA":1810},{"trials":1793,"activeCount":101},[],{"trials":1795,"activeCount":101},[],{"trials":1797,"activeCount":101},[],{"trials":1799,"activeCount":101},[],{"trials":1801,"activeCount":101},[1802],{"nctId":1803,"briefTitle":1804,"status":219,"phases":1805,"primaryCompletion":1806,"completion":1806,"start":1463,"enrollment":386,"conditions":1807,"interventions":1809},"NCT00401167","Memantine for Agitation and Aggression in Severe Alzheimer's Disease",[92],"2010-01",[1808],"Alzheimer's Disease",[1790],{"trials":1811,"activeCount":101},[],{"intervention":1813,"totalTrials":155,"cells":1814},"Multiple vs. single courses of antenatalcorticosteroids",{"EARLY_PHASE1":1815,"PHASE1":1817,"PHASE2":1819,"PHASE3":1821,"PHASE4":1823,"NA":1834},{"trials":1816,"activeCount":101},[],{"trials":1818,"activeCount":101},[],{"trials":1820,"activeCount":101},[],{"trials":1822,"activeCount":101},[],{"trials":1824,"activeCount":101},[1825],{"nctId":1826,"briefTitle":1827,"status":219,"phases":1828,"primaryCompletion":1645,"completion":222,"start":1829,"enrollment":1830,"conditions":1831,"interventions":1833},"NCT00187382","Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study (MACS)",[92],"2001-04",1858,[1832],"Pregnancies at Increased Risk of Preterm Birth",[1813],{"trials":1835,"activeCount":101},[],{"intervention":681,"totalTrials":155,"cells":1837},{"EARLY_PHASE1":1838,"PHASE1":1840,"PHASE2":1842,"PHASE3":1844,"PHASE4":1846,"NA":1852},{"trials":1839,"activeCount":101},[],{"trials":1841,"activeCount":101},[],{"trials":1843,"activeCount":101},[],{"trials":1845,"activeCount":101},[],{"trials":1847,"activeCount":101},[1848],{"nctId":672,"briefTitle":673,"status":219,"phases":1849,"completion":675,"start":676,"enrollment":677,"conditions":1850,"interventions":1851},[92],[679,30],[681,646],{"trials":1853,"activeCount":101},[],{"intervention":1855,"totalTrials":155,"cells":1856},"Gabapentin",{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1863,"PHASE4":1865,"NA":1873},{"trials":1858,"activeCount":101},[],{"trials":1860,"activeCount":101},[],{"trials":1862,"activeCount":101},[],{"trials":1864,"activeCount":101},[],{"trials":1866,"activeCount":101},[1867],{"nctId":1868,"briefTitle":1869,"status":219,"phases":1870,"primaryCompletion":1806,"completion":1806,"start":1645,"enrollment":257,"conditions":1871,"interventions":1872},"NCT00982800","Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?",[92],[18],[1855],{"trials":1874,"activeCount":101},[],{"intervention":1876,"totalTrials":155,"cells":1877},"Antibiotic",{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1884,"PHASE4":1886,"NA":1901},{"trials":1879,"activeCount":101},[],{"trials":1881,"activeCount":101},[],{"trials":1883,"activeCount":101},[],{"trials":1885,"activeCount":101},[],{"trials":1887,"activeCount":101},[1888],{"nctId":1889,"briefTitle":1890,"status":622,"phases":1891,"primaryCompletion":1892,"completion":1893,"start":1894,"enrollment":1895,"conditions":1896,"interventions":1900},"NCT04707092","Use of Preoperative and Postoperative Antimicrobial Treatment",[92],"2022-06-30","2022-12-31","2021-06-01",304,[1897,1898,1899],"Ear Infection Bacterial","Surgical Site Infection","Antibiotic Side Effect",[1876],{"trials":1902,"activeCount":101},[],{"intervention":1904,"totalTrials":97,"cells":1905},"perindopril",{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1910,"PHASE3":1922,"PHASE4":1935,"NA":1937},{"trials":1907,"activeCount":101},[],{"trials":1909,"activeCount":101},[],{"trials":1911,"activeCount":101},[1912],{"nctId":1913,"briefTitle":1914,"status":209,"phases":1915,"primaryCompletion":1916,"completion":1916,"start":293,"enrollment":1917,"conditions":1918,"interventions":1919},"NCT02085265","Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients",[90],"2025-02-28",23,[1808],[1920,1921],"Perindopril","Telmisartan",{"trials":1923,"activeCount":101},[1924],{"nctId":1925,"briefTitle":1926,"status":219,"phases":1927,"primaryCompletion":213,"completion":1928,"start":1929,"enrollment":1917,"conditions":1930,"interventions":1933},"NCT02729441","Perindopril vs Ramipril for Persistence in MAU Reduction Study",[91],"2012-12","2010-04",[1931,1932],"Diabetes","Microalbuminuria",[1934,1904],"ramipril",{"trials":1936,"activeCount":101},[],{"trials":1938,"activeCount":101},[],{"intervention":1940,"totalTrials":97,"cells":1941},"Lithium Carbonate",{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1946,"PHASE3":1960,"PHASE4":1969,"NA":1971},{"trials":1943,"activeCount":101},[],{"trials":1945,"activeCount":101},[],{"trials":1947,"activeCount":101},[1948],{"nctId":1949,"briefTitle":1950,"status":622,"phases":1951,"primaryCompletion":1952,"completion":1953,"start":1954,"enrollment":1955,"conditions":1956,"interventions":1958},"NCT02999022","Lithium for Fracture Treatment: a Double Blind Randomized Controlled Trial (LiFT)",[90],"2024-12","2025-06","2017-07-21",160,[1957],"Fractures",[1940,1959],"Lactose Placebo",{"trials":1961,"activeCount":101},[1962],{"nctId":1963,"briefTitle":1964,"status":219,"phases":1965,"primaryCompletion":1966,"completion":1966,"start":1929,"enrollment":25,"conditions":1967,"interventions":1968},"NCT01112813","The Neurotrophic Effects of Lithium Carbonate Following Stroke: A Feasibility Study",[91],"2017-07-25",[21],[1940],{"trials":1970,"activeCount":101},[],{"trials":1972,"activeCount":101},[],{"intervention":1974,"totalTrials":97,"cells":1975},"dexamethasone",{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1989,"PHASE3":1991,"PHASE4":2009,"NA":2011},{"trials":1977,"activeCount":101},[],{"trials":1979,"activeCount":101},[1980],{"nctId":1981,"briefTitle":1982,"status":219,"phases":1983,"primaryCompletion":1984,"completion":1984,"start":1985,"enrollment":1986,"conditions":1987,"interventions":1988},"NCT00438828","Dexamethasone for the Prophylaxis of Pain Flare Study",[89],"2011-07","2007-02",61,[296],[1974],{"trials":1990,"activeCount":101},[],{"trials":1992,"activeCount":101},[1993],{"nctId":1994,"briefTitle":1995,"status":622,"phases":1996,"primaryCompletion":1997,"completion":1998,"start":1999,"enrollment":2000,"conditions":2001,"interventions":2003},"NCT04330690","Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial",[91],"2024-03-10","2024-05-18","2020-03-18",2900,[2002],"COVID-19",[2004,2005,2006,2007,2008],"Artesunate","Imatinib","Infliximab","Dexamethasone","LSALT Peptide",{"trials":2010,"activeCount":101},[],{"trials":2012,"activeCount":101},[],{"intervention":2014,"totalTrials":155,"cells":2015},"Magnesium sulfate and then Digoxin",{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2020,"PHASE3":2022,"PHASE4":2035,"NA":2037},{"trials":2017,"activeCount":101},[],{"trials":2019,"activeCount":101},[],{"trials":2021,"activeCount":101},[],{"trials":2023,"activeCount":101},[2024],{"nctId":2025,"briefTitle":2026,"status":622,"phases":2027,"primaryCompletion":2028,"completion":2029,"start":2030,"enrollment":636,"conditions":2031,"interventions":2033},"NCT05287191","MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care",[91],"2025-10-31","2026-04-30","2022-01-05",[2032],"Atrial Fibrillation New Onset",[2014,2034],"Amiodarone",{"trials":2036,"activeCount":101},[],{"trials":2038,"activeCount":101},[],{"intervention":2034,"totalTrials":155,"cells":2040},{"EARLY_PHASE1":2041,"PHASE1":2043,"PHASE2":2045,"PHASE3":2047,"PHASE4":2053,"NA":2055},{"trials":2042,"activeCount":101},[],{"trials":2044,"activeCount":101},[],{"trials":2046,"activeCount":101},[],{"trials":2048,"activeCount":101},[2049],{"nctId":2025,"briefTitle":2026,"status":622,"phases":2050,"primaryCompletion":2028,"completion":2029,"start":2030,"enrollment":636,"conditions":2051,"interventions":2052},[91],[2032],[2014,2034],{"trials":2054,"activeCount":101},[],{"trials":2056,"activeCount":101},[],{"intervention":300,"totalTrials":155,"cells":2058},{"EARLY_PHASE1":2059,"PHASE1":2061,"PHASE2":2063,"PHASE3":2065,"PHASE4":2071,"NA":2073},{"trials":2060,"activeCount":101},[],{"trials":2062,"activeCount":101},[],{"trials":2064,"activeCount":101},[],{"trials":2066,"activeCount":101},[2067],{"nctId":289,"briefTitle":290,"status":219,"phases":2068,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":2069,"interventions":2070},[91],[296,297,298],[300,301],{"trials":2072,"activeCount":101},[],{"trials":2074,"activeCount":101},[],{"intervention":2076,"totalTrials":155,"cells":2077},"Cholinesterase Inhibitor",{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2082,"PHASE3":2084,"PHASE4":2095,"NA":2097},{"trials":2079,"activeCount":101},[],{"trials":2081,"activeCount":101},[],{"trials":2083,"activeCount":101},[],{"trials":2085,"activeCount":101},[2086],{"nctId":2087,"briefTitle":2088,"status":219,"phases":2089,"primaryCompletion":2090,"completion":2091,"start":2092,"enrollment":677,"conditions":2093,"interventions":2094},"NCT02035982","Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease",[91],"2014-05","2015-09","2010-07",[1808,679],[2076],{"trials":2096,"activeCount":101},[],{"trials":2098,"activeCount":101},[],{"intervention":1934,"totalTrials":155,"cells":2100},{"EARLY_PHASE1":2101,"PHASE1":2103,"PHASE2":2105,"PHASE3":2107,"PHASE4":2113,"NA":2115},{"trials":2102,"activeCount":101},[],{"trials":2104,"activeCount":101},[],{"trials":2106,"activeCount":101},[],{"trials":2108,"activeCount":101},[2109],{"nctId":1925,"briefTitle":1926,"status":219,"phases":2110,"primaryCompletion":213,"completion":1928,"start":1929,"enrollment":1917,"conditions":2111,"interventions":2112},[91],[1931,1932],[1934,1904],{"trials":2114,"activeCount":101},[],{"trials":2116,"activeCount":101},[],{"intervention":2118,"totalTrials":155,"cells":2119},"Botulinum toxin A",{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2126,"PHASE4":2136,"NA":2138},{"trials":2121,"activeCount":101},[],{"trials":2123,"activeCount":101},[],{"trials":2125,"activeCount":101},[],{"trials":2127,"activeCount":101},[2128],{"nctId":2129,"briefTitle":2130,"status":219,"phases":2131,"primaryCompletion":223,"completion":223,"start":675,"enrollment":2132,"conditions":2133,"interventions":2135},"NCT01091727","Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity",[91],57,[2134],"Neurogenic Detrusor Overactivity",[2118],{"trials":2137,"activeCount":101},[],{"trials":2139,"activeCount":101},[],{"intervention":2141,"totalTrials":155,"cells":2142},"ezetimibe",{"EARLY_PHASE1":2143,"PHASE1":2145,"PHASE2":2147,"PHASE3":2149,"PHASE4":2165,"NA":2167},{"trials":2144,"activeCount":101},[],{"trials":2146,"activeCount":101},[],{"trials":2148,"activeCount":101},[],{"trials":2150,"activeCount":101},[2151],{"nctId":2152,"briefTitle":2153,"status":209,"phases":2154,"primaryCompletion":2155,"completion":2156,"start":2157,"enrollment":2158,"conditions":2159,"interventions":2161},"NCT00664469","INdians Followed for INtensive Lipid Lowering Treatment and Its safetY",[91],"2010-03","2010-11","2007-08",64,[2160],"Hypercholesterolemia",[2141,2162,2163,2164],"Comparator: Simvastatin 20, 40 and 80 mg","Comparator: Atorvastatin","Comparator: Rosuvastatin",{"trials":2166,"activeCount":101},[],{"trials":2168,"activeCount":101},[],{"intervention":2162,"totalTrials":155,"cells":2170},{"EARLY_PHASE1":2171,"PHASE1":2173,"PHASE2":2175,"PHASE3":2177,"PHASE4":2183,"NA":2185},{"trials":2172,"activeCount":101},[],{"trials":2174,"activeCount":101},[],{"trials":2176,"activeCount":101},[],{"trials":2178,"activeCount":101},[2179],{"nctId":2152,"briefTitle":2153,"status":209,"phases":2180,"primaryCompletion":2155,"completion":2156,"start":2157,"enrollment":2158,"conditions":2181,"interventions":2182},[91],[2160],[2141,2162,2163,2164],{"trials":2184,"activeCount":101},[],{"trials":2186,"activeCount":101},[],{"intervention":2163,"totalTrials":155,"cells":2188},{"EARLY_PHASE1":2189,"PHASE1":2191,"PHASE2":2193,"PHASE3":2195,"PHASE4":2201,"NA":2203},{"trials":2190,"activeCount":101},[],{"trials":2192,"activeCount":101},[],{"trials":2194,"activeCount":101},[],{"trials":2196,"activeCount":101},[2197],{"nctId":2152,"briefTitle":2153,"status":209,"phases":2198,"primaryCompletion":2155,"completion":2156,"start":2157,"enrollment":2158,"conditions":2199,"interventions":2200},[91],[2160],[2141,2162,2163,2164],{"trials":2202,"activeCount":101},[],{"trials":2204,"activeCount":101},[],{"intervention":2164,"totalTrials":155,"cells":2206},{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2213,"PHASE4":2219,"NA":2221},{"trials":2208,"activeCount":101},[],{"trials":2210,"activeCount":101},[],{"trials":2212,"activeCount":101},[],{"trials":2214,"activeCount":101},[2215],{"nctId":2152,"briefTitle":2153,"status":209,"phases":2216,"primaryCompletion":2155,"completion":2156,"start":2157,"enrollment":2158,"conditions":2217,"interventions":2218},[91],[2160],[2141,2162,2163,2164],{"trials":2220,"activeCount":101},[],{"trials":2222,"activeCount":101},[],{"intervention":2224,"totalTrials":155,"cells":2225},"Prehabilitation",{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2230,"PHASE3":2232,"PHASE4":2245,"NA":2247},{"trials":2227,"activeCount":101},[],{"trials":2229,"activeCount":101},[],{"trials":2231,"activeCount":101},[],{"trials":2233,"activeCount":101},[2234],{"nctId":2235,"briefTitle":2236,"status":219,"phases":2237,"primaryCompletion":2238,"completion":2238,"start":2239,"enrollment":708,"conditions":2240,"interventions":2244},"NCT03564171","Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer",[90,91],"2023-03-31","2018-07-18",[15,2241,2242,2243],"Rehabilitation","Neoadjuvant Therapy","Feasibility Studies",[2224],{"trials":2246,"activeCount":101},[],{"trials":2248,"activeCount":101},[],{"intervention":2250,"totalTrials":155,"cells":2251},"Variation in volume of local anesthetic",{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2256,"PHASE3":2258,"PHASE4":2269,"NA":2271},{"trials":2253,"activeCount":101},[],{"trials":2255,"activeCount":101},[],{"trials":2257,"activeCount":101},[],{"trials":2259,"activeCount":101},[2260],{"nctId":2261,"briefTitle":2262,"status":219,"phases":2263,"completion":2264,"start":2265,"enrollment":412,"conditions":2266,"interventions":2268},"NCT00497354","Does a Low Volume Ultrasound-Guided Technique Reduce Common Complications of Interscalene Brachial Plexus Block?",[91],"2007-12","2007-07",[2267],"Pain After Shoulder Surgery",[2250],{"trials":2270,"activeCount":101},[],{"trials":2272,"activeCount":101},[],{"intervention":2274,"totalTrials":155,"cells":2275},"Pfizer-BioNTech COVID-19 Vaccine",{"EARLY_PHASE1":2276,"PHASE1":2278,"PHASE2":2280,"PHASE3":2282,"PHASE4":2296,"NA":2298},{"trials":2277,"activeCount":101},[],{"trials":2279,"activeCount":101},[],{"trials":2281,"activeCount":101},[],{"trials":2283,"activeCount":101},[2284],{"nctId":2285,"briefTitle":2286,"status":209,"phases":2287,"primaryCompletion":2288,"completion":2289,"start":2290,"enrollment":2291,"conditions":2292,"interventions":2294},"NCT05022329","COVID-19 Vaccine Boosters in Patients With CKD",[90,91],"2022-05-11","2022-11-15","2021-09-30",273,[2293,2002],"Chronic Kidney Diseases",[2274,2295],"MODERNA SARS-CoV-2 Vaccine",{"trials":2297,"activeCount":101},[],{"trials":2299,"activeCount":101},[],{"intervention":2295,"totalTrials":155,"cells":2301},{"EARLY_PHASE1":2302,"PHASE1":2304,"PHASE2":2306,"PHASE3":2308,"PHASE4":2314,"NA":2316},{"trials":2303,"activeCount":101},[],{"trials":2305,"activeCount":101},[],{"trials":2307,"activeCount":101},[],{"trials":2309,"activeCount":101},[2310],{"nctId":2285,"briefTitle":2286,"status":209,"phases":2311,"primaryCompletion":2288,"completion":2289,"start":2290,"enrollment":2291,"conditions":2312,"interventions":2313},[90,91],[2293,2002],[2274,2295],{"trials":2315,"activeCount":101},[],{"trials":2317,"activeCount":101},[],{"intervention":2319,"totalTrials":155,"cells":2320},"hypertonic saline mixed Dextran",{"EARLY_PHASE1":2321,"PHASE1":2323,"PHASE2":2325,"PHASE3":2327,"PHASE4":2339,"NA":2341},{"trials":2322,"activeCount":101},[],{"trials":2324,"activeCount":101},[],{"trials":2326,"activeCount":101},[],{"trials":2328,"activeCount":101},[2329],{"nctId":2330,"briefTitle":2331,"status":219,"phases":2332,"primaryCompletion":2333,"completion":1984,"start":2334,"enrollment":2335,"conditions":2336,"interventions":2337},"NCT01642524","The Toronto Prehospital Hypertonic Resuscitation Head Injury and Multi Organ Dysfunction Trial (TOPHR HIT)",[91],"2006-01","2004-04",114,[512],[2319,2338],"Saline solution",{"trials":2340,"activeCount":101},[],{"trials":2342,"activeCount":101},[],{"intervention":2338,"totalTrials":155,"cells":2344},{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2351,"PHASE4":2357,"NA":2359},{"trials":2346,"activeCount":101},[],{"trials":2348,"activeCount":101},[],{"trials":2350,"activeCount":101},[],{"trials":2352,"activeCount":101},[2353],{"nctId":2330,"briefTitle":2331,"status":219,"phases":2354,"primaryCompletion":2333,"completion":1984,"start":2334,"enrollment":2335,"conditions":2355,"interventions":2356},[91],[512],[2319,2338],{"trials":2358,"activeCount":101},[],{"trials":2360,"activeCount":101},[],{"intervention":2362,"totalTrials":155,"cells":2363},"Pregabalin, Celecoxib",{"EARLY_PHASE1":2364,"PHASE1":2366,"PHASE2":2368,"PHASE3":2370,"PHASE4":2380,"NA":2382},{"trials":2365,"activeCount":101},[],{"trials":2367,"activeCount":101},[],{"trials":2369,"activeCount":101},[],{"trials":2371,"activeCount":101},[2372],{"nctId":2373,"briefTitle":2374,"status":219,"phases":2375,"primaryCompletion":1696,"completion":1696,"start":2376,"enrollment":386,"conditions":2377,"interventions":2379},"NCT00581685","Does Optimal Control of Pre-operative Chronic and Acute Pain Predict Improved Function After Orthopedic Surgery?",[91],"2008-01",[2378],"Osteoarthritis",[2362],{"trials":2381,"activeCount":101},[],{"trials":2383,"activeCount":101},[],{"intervention":2385,"totalTrials":155,"cells":2386},"Ferrous Sulfate 300Mg",{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2393,"PHASE4":2407,"NA":2409},{"trials":2388,"activeCount":101},[],{"trials":2390,"activeCount":101},[],{"trials":2392,"activeCount":101},[],{"trials":2394,"activeCount":101},[2395],{"nctId":2396,"briefTitle":2397,"status":219,"phases":2398,"primaryCompletion":2399,"completion":2399,"start":2400,"enrollment":2401,"conditions":2402,"interventions":2405},"NCT03725384","Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia",[91],"2022-01-26","2019-01-04",51,[2403,2404],"Anemia","Iron Deficiency Anemia",[2385,2406],"Vitamin C 500Mg",{"trials":2408,"activeCount":101},[],{"trials":2410,"activeCount":101},[],{"intervention":2406,"totalTrials":155,"cells":2412},{"EARLY_PHASE1":2413,"PHASE1":2415,"PHASE2":2417,"PHASE3":2419,"PHASE4":2425,"NA":2427},{"trials":2414,"activeCount":101},[],{"trials":2416,"activeCount":101},[],{"trials":2418,"activeCount":101},[],{"trials":2420,"activeCount":101},[2421],{"nctId":2396,"briefTitle":2397,"status":219,"phases":2422,"primaryCompletion":2399,"completion":2399,"start":2400,"enrollment":2401,"conditions":2423,"interventions":2424},[91],[2403,2404],[2385,2406],{"trials":2426,"activeCount":101},[],{"trials":2428,"activeCount":101},[],{"intervention":2004,"totalTrials":155,"cells":2430},{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2437,"PHASE4":2443,"NA":2445},{"trials":2432,"activeCount":101},[],{"trials":2434,"activeCount":101},[],{"trials":2436,"activeCount":101},[],{"trials":2438,"activeCount":101},[2439],{"nctId":1994,"briefTitle":1995,"status":622,"phases":2440,"primaryCompletion":1997,"completion":1998,"start":1999,"enrollment":2000,"conditions":2441,"interventions":2442},[91],[2002],[2004,2005,2006,2007,2008],{"trials":2444,"activeCount":101},[],{"trials":2446,"activeCount":101},[],{"intervention":2005,"totalTrials":155,"cells":2448},{"EARLY_PHASE1":2449,"PHASE1":2451,"PHASE2":2453,"PHASE3":2455,"PHASE4":2461,"NA":2463},{"trials":2450,"activeCount":101},[],{"trials":2452,"activeCount":101},[],{"trials":2454,"activeCount":101},[],{"trials":2456,"activeCount":101},[2457],{"nctId":1994,"briefTitle":1995,"status":622,"phases":2458,"primaryCompletion":1997,"completion":1998,"start":1999,"enrollment":2000,"conditions":2459,"interventions":2460},[91],[2002],[2004,2005,2006,2007,2008],{"trials":2462,"activeCount":101},[],{"trials":2464,"activeCount":101},[],{"intervention":2006,"totalTrials":155,"cells":2466},{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2471,"PHASE3":2473,"PHASE4":2479,"NA":2481},{"trials":2468,"activeCount":101},[],{"trials":2470,"activeCount":101},[],{"trials":2472,"activeCount":101},[],{"trials":2474,"activeCount":101},[2475],{"nctId":1994,"briefTitle":1995,"status":622,"phases":2476,"primaryCompletion":1997,"completion":1998,"start":1999,"enrollment":2000,"conditions":2477,"interventions":2478},[91],[2002],[2004,2005,2006,2007,2008],{"trials":2480,"activeCount":101},[],{"trials":2482,"activeCount":101},[],{"intervention":2008,"totalTrials":155,"cells":2484},{"EARLY_PHASE1":2485,"PHASE1":2487,"PHASE2":2489,"PHASE3":2491,"PHASE4":2497,"NA":2499},{"trials":2486,"activeCount":101},[],{"trials":2488,"activeCount":101},[],{"trials":2490,"activeCount":101},[],{"trials":2492,"activeCount":101},[2493],{"nctId":1994,"briefTitle":1995,"status":622,"phases":2494,"primaryCompletion":1997,"completion":1998,"start":1999,"enrollment":2000,"conditions":2495,"interventions":2496},[91],[2002],[2004,2005,2006,2007,2008],{"trials":2498,"activeCount":101},[],{"trials":2500,"activeCount":101},[],{"intervention":2502,"totalTrials":155,"cells":2503},"Oxandrolone",{"EARLY_PHASE1":2504,"PHASE1":2506,"PHASE2":2508,"PHASE3":2510,"PHASE4":2521,"NA":2523},{"trials":2505,"activeCount":101},[],{"trials":2507,"activeCount":101},[],{"trials":2509,"activeCount":101},[],{"trials":2511,"activeCount":101},[2512],{"nctId":2513,"briefTitle":2514,"status":1461,"phases":2515,"primaryCompletion":2516,"completion":2516,"start":2517,"enrollment":101,"conditions":2518,"interventions":2520},"NCT05516849","Placebo Versus Oxandrolone Supplementation in Trauma",[91],"2023-08-03","2022-05-19",[2519],"Trauma Injury",[2502],{"trials":2522,"activeCount":101},[],{"trials":2524,"activeCount":101},[],{"intervention":2526,"totalTrials":155,"cells":2527},"Erythropoietin",{"EARLY_PHASE1":2528,"PHASE1":2530,"PHASE2":2532,"PHASE3":2534,"PHASE4":2545,"NA":2547},{"trials":2529,"activeCount":101},[],{"trials":2531,"activeCount":101},[],{"trials":2533,"activeCount":101},[],{"trials":2535,"activeCount":101},[2536],{"nctId":2537,"briefTitle":2538,"status":209,"phases":2539,"primaryCompletion":2265,"completion":2265,"start":2540,"enrollment":2541,"conditions":2542,"interventions":2544},"NCT00220675","Erythropoietin Spinal Cord Compression Randomized Trial",[90,91],"2005-08",7,[2543],"Nerve Compression Syndromes",[2526],{"trials":2546,"activeCount":101},[],{"trials":2548,"activeCount":101},[],{"intervention":2550,"totalTrials":155,"cells":2551},"Triamcinolone Acetonide",{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2556,"PHASE3":2558,"PHASE4":2570,"NA":2572},{"trials":2553,"activeCount":101},[],{"trials":2555,"activeCount":101},[],{"trials":2557,"activeCount":101},[],{"trials":2559,"activeCount":101},[2560],{"nctId":2561,"briefTitle":2562,"status":219,"phases":2563,"primaryCompletion":2564,"completion":2565,"start":2566,"enrollment":2401,"conditions":2567,"interventions":2569},"NCT00565019","Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Dupuytren's Contracture",[91],"2011-08","2013-06","2007-11",[2568],"Dupuytren's Contracture",[2550],{"trials":2571,"activeCount":101},[],{"trials":2573,"activeCount":101},[],{"intervention":2575,"totalTrials":155,"cells":2576},"Antibiotic 1 arm",{"EARLY_PHASE1":2577,"PHASE1":2579,"PHASE2":2581,"PHASE3":2583,"PHASE4":2597,"NA":2599},{"trials":2578,"activeCount":101},[],{"trials":2580,"activeCount":101},[],{"trials":2582,"activeCount":101},[],{"trials":2584,"activeCount":101},[2585],{"nctId":2586,"briefTitle":2587,"status":219,"phases":2588,"primaryCompletion":2589,"completion":2589,"start":2590,"enrollment":2591,"conditions":2592,"interventions":2595},"NCT04549311","Perianal Abscess Recurrence and Fistula Formation: Antibiotics Following Incision and Drainage Trial",[91],"2023-01-22","2021-11-18",15,[2593,2594],"Perianal Abscess","Perianal Fistula",[2575,2596],"Antibiotic 2 arm",{"trials":2598,"activeCount":101},[],{"trials":2600,"activeCount":101},[],{"intervention":2596,"totalTrials":155,"cells":2602},{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2607,"PHASE3":2609,"PHASE4":2615,"NA":2617},{"trials":2604,"activeCount":101},[],{"trials":2606,"activeCount":101},[],{"trials":2608,"activeCount":101},[],{"trials":2610,"activeCount":101},[2611],{"nctId":2586,"briefTitle":2587,"status":219,"phases":2612,"primaryCompletion":2589,"completion":2589,"start":2590,"enrollment":2591,"conditions":2613,"interventions":2614},[91],[2593,2594],[2575,2596],{"trials":2616,"activeCount":101},[],{"trials":2618,"activeCount":101},[],{"intervention":351,"totalTrials":155,"cells":2620},{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2625,"PHASE3":2627,"PHASE4":2633,"NA":2635},{"trials":2622,"activeCount":101},[],{"trials":2624,"activeCount":101},[],{"trials":2626,"activeCount":101},[],{"trials":2628,"activeCount":101},[2629],{"nctId":341,"briefTitle":342,"status":219,"phases":2630,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":2631,"interventions":2632},[90,91],[349],[351,308],{"trials":2634,"activeCount":101},[],{"trials":2636,"activeCount":101},[],{"intervention":2638,"totalTrials":97,"cells":2639},"ruxolitinib",{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2668,"PHASE4":2670,"NA":2672},{"trials":2641,"activeCount":101},[],{"trials":2643,"activeCount":101},[],{"trials":2645,"activeCount":101},[2646,2657],{"nctId":2647,"briefTitle":2648,"status":622,"phases":2649,"primaryCompletion":2650,"completion":2651,"start":2652,"enrollment":719,"conditions":2653,"interventions":2655},"NCT02912754","Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients",[89,90],"2018-12","2019-08","2017-03",[2654],"Leukemia, Lymphocytic, Chronic, B-Cell",[2638,2656],"ibrutinib",{"nctId":2658,"briefTitle":2659,"status":219,"phases":2660,"primaryCompletion":2661,"completion":2661,"start":2662,"enrollment":2663,"conditions":2664,"interventions":2666},"NCT02015208","Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia",[89,90],"2015-07","2014-04",13,[2665],"Chronic Lymphocytic Leukemia",[2667],"Ruxolitinib",{"trials":2669,"activeCount":101},[],{"trials":2671,"activeCount":101},[],{"trials":2673,"activeCount":101},[],{"intervention":2675,"totalTrials":97,"cells":2676},"Avelumab",{"EARLY_PHASE1":2677,"PHASE1":2679,"PHASE2":2681,"PHASE3":2703,"PHASE4":2705,"NA":2707},{"trials":2678,"activeCount":101},[],{"trials":2680,"activeCount":101},[],{"trials":2682,"activeCount":101},[2683,2693],{"nctId":2684,"briefTitle":2685,"status":219,"phases":2686,"primaryCompletion":2687,"completion":2688,"start":2689,"enrollment":31,"conditions":2690,"interventions":2692},"NCT03278405","Avelumab in G3 NEC",[89,90],"2019-08-09","2020-03-12","2017-11-15",[2691],"Neuroendocrine Carcinoma",[2675],{"nctId":2694,"briefTitle":2695,"status":219,"phases":2696,"primaryCompletion":2697,"completion":2698,"start":2689,"enrollment":2699,"conditions":2700,"interventions":2702},"NCT03278379","Avelumab in G2-3 NET",[90],"2021-07-26","2023-07-06",17,[2701],"Neuroendocrine Tumors",[2675],{"trials":2704,"activeCount":101},[],{"trials":2706,"activeCount":101},[],{"trials":2708,"activeCount":101},[],{"intervention":2710,"totalTrials":97,"cells":2711},"Pembrolizumab",{"EARLY_PHASE1":2712,"PHASE1":2714,"PHASE2":2716,"PHASE3":2742,"PHASE4":2744,"NA":2746},{"trials":2713,"activeCount":101},[],{"trials":2715,"activeCount":101},[],{"trials":2717,"activeCount":101},[2718,2728],{"nctId":2719,"briefTitle":2720,"status":219,"phases":2721,"primaryCompletion":2722,"completion":2723,"start":2724,"enrollment":1160,"conditions":2725,"interventions":2727},"NCT02599779","A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients",[90],"2021-08","2021-08-05","2016-12",[2726],"Stage IV Renal Cell Cancer AJCC V7",[2710],{"nctId":2729,"briefTitle":2730,"status":219,"phases":2731,"primaryCompletion":2732,"completion":2733,"start":2734,"enrollment":19,"conditions":2735,"interventions":2739},"NCT03349450","DPX-Survivac and Checkpoint Inhibitor in DLBCL",[90],"2021-10-31","2023-07-18","2018-03-13",[2736,2737,2738],"Adult Diffuse Large Cell Lymphoma","Recurrent","Adult Refractory Diffuse Large B-Cell Lymphoma",[2740,2710,2741],"DPX-Survivac","Cyclophosphamide 50mg",{"trials":2743,"activeCount":101},[],{"trials":2745,"activeCount":101},[],{"trials":2747,"activeCount":101},[],{"intervention":373,"totalTrials":97,"cells":2749},{"EARLY_PHASE1":2750,"PHASE1":2756,"PHASE2":2758,"PHASE3":2770,"PHASE4":2772,"NA":2774},{"trials":2751,"activeCount":101},[2752],{"nctId":362,"briefTitle":363,"status":219,"phases":2753,"primaryCompletion":365,"completion":365,"start":366,"enrollment":36,"conditions":2754,"interventions":2755},[88],[33,368,369,370,371],[357,373],{"trials":2757,"activeCount":101},[],{"trials":2759,"activeCount":101},[2760],{"nctId":2761,"briefTitle":2762,"status":209,"phases":2763,"primaryCompletion":2764,"completion":2765,"start":2766,"enrollment":19,"conditions":2767,"interventions":2768},"NCT02351869","Nitrous Oxide as a Putative Novel Dual-Mechanism Treatment for Bipolar Disorder",[90],"2020-02-01","2020-06-07","2015-08",[35],[2769,373],"Nitrous Oxide",{"trials":2771,"activeCount":101},[],{"trials":2773,"activeCount":101},[],{"trials":2775,"activeCount":101},[],{"intervention":2777,"totalTrials":155,"cells":2778},"Sunitinib",{"EARLY_PHASE1":2779,"PHASE1":2781,"PHASE2":2783,"PHASE3":2795,"PHASE4":2797,"NA":2799},{"trials":2780,"activeCount":101},[],{"trials":2782,"activeCount":101},[],{"trials":2784,"activeCount":101},[2785],{"nctId":2786,"briefTitle":2787,"status":219,"phases":2788,"primaryCompletion":2789,"completion":2789,"start":2790,"enrollment":2791,"conditions":2792,"interventions":2794},"NCT01499121","Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule",[90],"2017-09-30","2012-05",117,[2793],"Clear Cell, Metastatic Renal Cell Carcinoma",[2777],{"trials":2796,"activeCount":101},[],{"trials":2798,"activeCount":101},[],{"trials":2800,"activeCount":101},[],{"intervention":2802,"totalTrials":155,"cells":2803},"Everolimus",{"EARLY_PHASE1":2804,"PHASE1":2806,"PHASE2":2808,"PHASE3":2820,"PHASE4":2822,"NA":2824},{"trials":2805,"activeCount":101},[],{"trials":2807,"activeCount":101},[],{"trials":2809,"activeCount":101},[2810],{"nctId":2811,"briefTitle":2812,"status":219,"phases":2813,"primaryCompletion":2814,"completion":2815,"start":2816,"enrollment":2699,"conditions":2817,"interventions":2819},"NCT02205515","An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis",[89,90],"2021-09","2021-10","2016-03",[2818],"Carcinoma, Neuroendocrine",[2802],{"trials":2821,"activeCount":101},[],{"trials":2823,"activeCount":101},[],{"trials":2825,"activeCount":101},[],{"intervention":2827,"totalTrials":155,"cells":2828},"N-Acetyl Cysteine",{"EARLY_PHASE1":2829,"PHASE1":2831,"PHASE2":2833,"PHASE3":2842,"PHASE4":2844,"NA":2846},{"trials":2830,"activeCount":101},[],{"trials":2832,"activeCount":101},[],{"trials":2834,"activeCount":101},[2835],{"nctId":2836,"briefTitle":2837,"status":622,"phases":2838,"primaryCompletion":624,"completion":624,"start":2839,"enrollment":324,"conditions":2840,"interventions":2841},"NCT04291209","Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.",[89,90],"2020-02-26",[747],[2827],{"trials":2843,"activeCount":101},[],{"trials":2845,"activeCount":101},[],{"trials":2847,"activeCount":101},[],{"intervention":2849,"totalTrials":155,"cells":2850},"Aprepitant",{"EARLY_PHASE1":2851,"PHASE1":2853,"PHASE2":2855,"PHASE3":2868,"PHASE4":2870,"NA":2872},{"trials":2852,"activeCount":101},[],{"trials":2854,"activeCount":101},[],{"trials":2856,"activeCount":101},[2857],{"nctId":2858,"briefTitle":2859,"status":209,"phases":2860,"primaryCompletion":2861,"completion":2861,"start":1484,"enrollment":2862,"conditions":2863,"interventions":2866},"NCT01183481","Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study",[90],"2013-03",19,[2864,2865],"Nausea","Vomiting",[2849,2867],"Granisetron",{"trials":2869,"activeCount":101},[],{"trials":2871,"activeCount":101},[],{"trials":2873,"activeCount":101},[],{"intervention":2867,"totalTrials":155,"cells":2875},{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2880,"PHASE3":2886,"PHASE4":2888,"NA":2890},{"trials":2877,"activeCount":101},[],{"trials":2879,"activeCount":101},[],{"trials":2881,"activeCount":101},[2882],{"nctId":2858,"briefTitle":2859,"status":209,"phases":2883,"primaryCompletion":2861,"completion":2861,"start":1484,"enrollment":2862,"conditions":2884,"interventions":2885},[90],[2864,2865],[2849,2867],{"trials":2887,"activeCount":101},[],{"trials":2889,"activeCount":101},[],{"trials":2891,"activeCount":101},[],{"intervention":2893,"totalTrials":155,"cells":2894},"TXA",{"EARLY_PHASE1":2895,"PHASE1":2897,"PHASE2":2899,"PHASE3":2910,"PHASE4":2912,"NA":2914},{"trials":2896,"activeCount":101},[],{"trials":2898,"activeCount":101},[],{"trials":2900,"activeCount":101},[2901],{"nctId":2902,"briefTitle":2903,"status":622,"phases":2904,"primaryCompletion":117,"completion":2905,"start":2906,"enrollment":386,"conditions":2907,"interventions":2909},"NCT03069859","Use of TXA to Prevent Postpartum Hemorrhage",[90],"2022-12","2018-03-06",[2908],"Post Partum Hemorrhage",[2893],{"trials":2911,"activeCount":101},[],{"trials":2913,"activeCount":101},[],{"trials":2915,"activeCount":101},[],{"intervention":2656,"totalTrials":155,"cells":2917},{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2922,"PHASE3":2928,"PHASE4":2930,"NA":2932},{"trials":2919,"activeCount":101},[],{"trials":2921,"activeCount":101},[],{"trials":2923,"activeCount":101},[2924],{"nctId":2647,"briefTitle":2648,"status":622,"phases":2925,"primaryCompletion":2650,"completion":2651,"start":2652,"enrollment":719,"conditions":2926,"interventions":2927},[89,90],[2654],[2638,2656],{"trials":2929,"activeCount":101},[],{"trials":2931,"activeCount":101},[],{"trials":2933,"activeCount":101},[],{"intervention":2935,"totalTrials":155,"cells":2936},"Intravenous N-acetylcysteine",{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2941,"PHASE3":2953,"PHASE4":2955,"NA":2957},{"trials":2938,"activeCount":101},[],{"trials":2940,"activeCount":101},[],{"trials":2942,"activeCount":101},[2943],{"nctId":2944,"briefTitle":2945,"status":219,"phases":2946,"completion":2540,"start":2947,"enrollment":2948,"conditions":2949,"interventions":2952},"NCT00187330","A Study of The Effectiveness of N-Acetylcysteine in Kidney Protection Following Cardiopulmonary Bypass",[90],"2004-03",104,[2950,2951],"Heart Disease","Renal Insufficiency",[2935],{"trials":2954,"activeCount":101},[],{"trials":2956,"activeCount":101},[],{"trials":2958,"activeCount":101},[],{"intervention":2960,"totalTrials":155,"cells":2961},"Withania somnifera",{"EARLY_PHASE1":2962,"PHASE1":2964,"PHASE2":2966,"PHASE3":2978,"PHASE4":2980,"NA":2982},{"trials":2963,"activeCount":101},[],{"trials":2965,"activeCount":101},[],{"trials":2967,"activeCount":101},[2968],{"nctId":2969,"briefTitle":2970,"status":622,"phases":2971,"primaryCompletion":2972,"completion":2973,"start":2974,"enrollment":2975,"conditions":2976,"interventions":2977},"NCT05031351","NF-κB Inhibition in Amyotrophic Lateral Sclerosis",[90],"2022-07","2022-09","2021-10-19",75,[1099],[2960],{"trials":2979,"activeCount":101},[],{"trials":2981,"activeCount":101},[],{"trials":2983,"activeCount":101},[],{"intervention":2985,"totalTrials":155,"cells":2986},"Deferasirox + Azacitidine",{"EARLY_PHASE1":2987,"PHASE1":2989,"PHASE2":2991,"PHASE3":3002,"PHASE4":3004,"NA":3006},{"trials":2988,"activeCount":101},[],{"trials":2990,"activeCount":101},[],{"trials":2992,"activeCount":101},[2993],{"nctId":2994,"briefTitle":2995,"status":209,"phases":2996,"primaryCompletion":2997,"completion":2997,"start":293,"enrollment":155,"conditions":2998,"interventions":3000},"NCT02038816","Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)",[90],"2016-09-29",[2999],"Myelodysplastic Syndromes",[2985,3001],"Azacitidine",{"trials":3003,"activeCount":101},[],{"trials":3005,"activeCount":101},[],{"trials":3007,"activeCount":101},[],{"intervention":3001,"totalTrials":155,"cells":3009},{"EARLY_PHASE1":3010,"PHASE1":3012,"PHASE2":3014,"PHASE3":3020,"PHASE4":3022,"NA":3024},{"trials":3011,"activeCount":101},[],{"trials":3013,"activeCount":101},[],{"trials":3015,"activeCount":101},[3016],{"nctId":2994,"briefTitle":2995,"status":209,"phases":3017,"primaryCompletion":2997,"completion":2997,"start":293,"enrollment":155,"conditions":3018,"interventions":3019},[90],[2999],[2985,3001],{"trials":3021,"activeCount":101},[],{"trials":3023,"activeCount":101},[],{"trials":3025,"activeCount":101},[],{"intervention":3027,"totalTrials":155,"cells":3028},"r-HuEPO",{"EARLY_PHASE1":3029,"PHASE1":3031,"PHASE2":3033,"PHASE3":3046,"PHASE4":3048,"NA":3050},{"trials":3030,"activeCount":101},[],{"trials":3032,"activeCount":101},[],{"trials":3034,"activeCount":101},[3035],{"nctId":3036,"briefTitle":3037,"status":219,"phases":3038,"primaryCompletion":3039,"completion":3039,"start":3040,"enrollment":3041,"conditions":3042,"interventions":3045},"NCT00744445","Erythropoietin Therapy in Patients With Chronic Renal Failure: A Study of Time Dependent Activity",[90],"1998-08","1993-10",46,[3043,3044,2403],"Hemodialysis","Chronic Renal Failure",[3027],{"trials":3047,"activeCount":101},[],{"trials":3049,"activeCount":101},[],{"trials":3051,"activeCount":101},[],{"intervention":3053,"totalTrials":155,"cells":3054},"EVUSHELD",{"EARLY_PHASE1":3055,"PHASE1":3057,"PHASE2":3059,"PHASE3":3070,"PHASE4":3072,"NA":3074},{"trials":3056,"activeCount":101},[],{"trials":3058,"activeCount":101},[],{"trials":3060,"activeCount":101},[3061],{"nctId":3062,"briefTitle":3063,"status":1461,"phases":3064,"primaryCompletion":3065,"completion":3066,"start":3067,"enrollment":101,"conditions":3068,"interventions":3069},"NCT05465876","Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL",[90],"2024-10","2025-10","2023-10",[2665,2002],[3053],{"trials":3071,"activeCount":101},[],{"trials":3073,"activeCount":101},[],{"trials":3075,"activeCount":101},[],{"intervention":2740,"totalTrials":155,"cells":3077},{"EARLY_PHASE1":3078,"PHASE1":3080,"PHASE2":3082,"PHASE3":3088,"PHASE4":3090,"NA":3092},{"trials":3079,"activeCount":101},[],{"trials":3081,"activeCount":101},[],{"trials":3083,"activeCount":101},[3084],{"nctId":2729,"briefTitle":2730,"status":219,"phases":3085,"primaryCompletion":2732,"completion":2733,"start":2734,"enrollment":19,"conditions":3086,"interventions":3087},[90],[2736,2737,2738],[2740,2710,2741],{"trials":3089,"activeCount":101},[],{"trials":3091,"activeCount":101},[],{"trials":3093,"activeCount":101},[],{"intervention":2741,"totalTrials":155,"cells":3095},{"EARLY_PHASE1":3096,"PHASE1":3098,"PHASE2":3100,"PHASE3":3106,"PHASE4":3108,"NA":3110},{"trials":3097,"activeCount":101},[],{"trials":3099,"activeCount":101},[],{"trials":3101,"activeCount":101},[3102],{"nctId":2729,"briefTitle":2730,"status":219,"phases":3103,"primaryCompletion":2732,"completion":2733,"start":2734,"enrollment":19,"conditions":3104,"interventions":3105},[90],[2736,2737,2738],[2740,2710,2741],{"trials":3107,"activeCount":101},[],{"trials":3109,"activeCount":101},[],{"trials":3111,"activeCount":101},[],{"intervention":3113,"totalTrials":155,"cells":3114},"Vemurafenib",{"EARLY_PHASE1":3115,"PHASE1":3117,"PHASE2":3119,"PHASE3":3129,"PHASE4":3131,"NA":3133},{"trials":3116,"activeCount":101},[],{"trials":3118,"activeCount":101},[],{"trials":3120,"activeCount":101},[3121],{"nctId":3122,"briefTitle":3123,"status":622,"phases":3124,"primaryCompletion":3125,"completion":3125,"start":2766,"enrollment":294,"conditions":3126,"interventions":3127},"NCT02036086","Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases",[90],"2024-01-31",[617],[3113,3128],"Cobimetinib",{"trials":3130,"activeCount":101},[],{"trials":3132,"activeCount":101},[],{"trials":3134,"activeCount":101},[],{"intervention":3128,"totalTrials":155,"cells":3136},{"EARLY_PHASE1":3137,"PHASE1":3139,"PHASE2":3141,"PHASE3":3147,"PHASE4":3149,"NA":3151},{"trials":3138,"activeCount":101},[],{"trials":3140,"activeCount":101},[],{"trials":3142,"activeCount":101},[3143],{"nctId":3122,"briefTitle":3123,"status":622,"phases":3144,"primaryCompletion":3125,"completion":3125,"start":2766,"enrollment":294,"conditions":3145,"interventions":3146},[90],[617],[3113,3128],{"trials":3148,"activeCount":101},[],{"trials":3150,"activeCount":101},[],{"trials":3152,"activeCount":101},[],{"intervention":3154,"totalTrials":155,"cells":3155},"Domperidone maleate",{"EARLY_PHASE1":3156,"PHASE1":3158,"PHASE2":3160,"PHASE3":3170,"PHASE4":3172,"NA":3174},{"trials":3157,"activeCount":101},[],{"trials":3159,"activeCount":101},[],{"trials":3161,"activeCount":101},[3162],{"nctId":3163,"briefTitle":3164,"status":219,"phases":3165,"primaryCompletion":3166,"completion":2816,"start":2790,"enrollment":146,"conditions":3167,"interventions":3169},"NCT01512225","Enhancing Breast Milk Production With Domperidone in Mothers of Preterm Neonates",[90],"2015-10",[3168],"Low Milk Supply",[3154,3154],{"trials":3171,"activeCount":101},[],{"trials":3173,"activeCount":101},[],{"trials":3175,"activeCount":101},[],{"intervention":3177,"totalTrials":155,"cells":3178},"Fibrinogen concentrate",{"EARLY_PHASE1":3179,"PHASE1":3181,"PHASE2":3183,"PHASE3":3198,"PHASE4":3200,"NA":3202},{"trials":3180,"activeCount":101},[],{"trials":3182,"activeCount":101},[],{"trials":3184,"activeCount":101},[3185],{"nctId":3186,"briefTitle":3187,"status":219,"phases":3188,"primaryCompletion":3189,"completion":3189,"start":3190,"enrollment":11,"conditions":3191,"interventions":3197},"NCT02203968","Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST)",[89,90],"2015-12","2014-10",[3192,3193,3194,3195,3196],"Trauma","Injury","Bleeding","Haemorrhage","Coagulopathy",[3177],{"trials":3199,"activeCount":101},[],{"trials":3201,"activeCount":101},[],{"trials":3203,"activeCount":101},[],{"intervention":3205,"totalTrials":155,"cells":3206},"Y90 Ibritumomab Tiuxetan RIT",{"EARLY_PHASE1":3207,"PHASE1":3209,"PHASE2":3211,"PHASE3":3222,"PHASE4":3224,"NA":3226},{"trials":3208,"activeCount":101},[],{"trials":3210,"activeCount":101},[],{"trials":3212,"activeCount":101},[3213],{"nctId":3214,"briefTitle":3215,"status":219,"phases":3216,"primaryCompletion":3217,"completion":3217,"start":3218,"enrollment":3219,"conditions":3220,"interventions":3221},"NCT01446562","Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma",[90],"2016-05","2007-05",34,[721],[3205],{"trials":3223,"activeCount":101},[],{"trials":3225,"activeCount":101},[],{"trials":3227,"activeCount":101},[],{"intervention":2769,"totalTrials":155,"cells":3229},{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3234,"PHASE3":3240,"PHASE4":3242,"NA":3244},{"trials":3231,"activeCount":101},[],{"trials":3233,"activeCount":101},[],{"trials":3235,"activeCount":101},[3236],{"nctId":2761,"briefTitle":2762,"status":209,"phases":3237,"primaryCompletion":2764,"completion":2765,"start":2766,"enrollment":19,"conditions":3238,"interventions":3239},[90],[35],[2769,373],{"trials":3241,"activeCount":101},[],{"trials":3243,"activeCount":101},[],{"trials":3245,"activeCount":101},[],{"intervention":3247,"totalTrials":155,"cells":3248},"Paclitaxel",{"EARLY_PHASE1":3249,"PHASE1":3251,"PHASE2":3253,"PHASE3":3265,"PHASE4":3267,"NA":3269},{"trials":3250,"activeCount":101},[],{"trials":3252,"activeCount":101},[],{"trials":3254,"activeCount":101},[3255],{"nctId":3256,"briefTitle":3257,"status":219,"phases":3258,"primaryCompletion":3259,"completion":3259,"start":3260,"enrollment":3261,"conditions":3262,"interventions":3264},"NCT00683059","Single Agent Abraxane as Second Line Therapy in Bladder Cancer",[90],"2012-06","2008-03",48,[3263],"Transitional Cell Carcinoma",[3247],{"trials":3266,"activeCount":101},[],{"trials":3268,"activeCount":101},[],{"trials":3270,"activeCount":101},[],{"intervention":1921,"totalTrials":155,"cells":3272},{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3277,"PHASE3":3283,"PHASE4":3285,"NA":3287},{"trials":3274,"activeCount":101},[],{"trials":3276,"activeCount":101},[],{"trials":3278,"activeCount":101},[3279],{"nctId":1913,"briefTitle":1914,"status":209,"phases":3280,"primaryCompletion":1916,"completion":1916,"start":293,"enrollment":1917,"conditions":3281,"interventions":3282},[90],[1808],[1920,1921],{"trials":3284,"activeCount":101},[],{"trials":3286,"activeCount":101},[],{"trials":3288,"activeCount":101},[],{"intervention":3290,"totalTrials":155,"cells":3291},"Pimonidazole",{"EARLY_PHASE1":3292,"PHASE1":3294,"PHASE2":3296,"PHASE3":3308,"PHASE4":3310,"NA":3312},{"trials":3293,"activeCount":101},[],{"trials":3295,"activeCount":101},[],{"trials":3297,"activeCount":101},[3298],{"nctId":3299,"briefTitle":3300,"status":3301,"phases":3302,"primaryCompletion":3303,"completion":1952,"start":3304,"enrollment":31,"conditions":3305,"interventions":3307},"NCT03181035","Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer","SUSPENDED",[89,90],"2024-09","2018-01-25",[3306],"Tongue Cancer",[3290],{"trials":3309,"activeCount":101},[],{"trials":3311,"activeCount":101},[],{"trials":3313,"activeCount":101},[],{"intervention":3315,"totalTrials":155,"cells":3316},"Curcumin",{"EARLY_PHASE1":3317,"PHASE1":3319,"PHASE2":3321,"PHASE3":3330,"PHASE4":3332,"NA":3334},{"trials":3318,"activeCount":101},[],{"trials":3320,"activeCount":101},[],{"trials":3322,"activeCount":101},[3323],{"nctId":3324,"briefTitle":3325,"status":209,"phases":3326,"primaryCompletion":3327,"completion":3327,"start":1695,"enrollment":2541,"conditions":3328,"interventions":3329},"NCT01928043","Adjunctive Curcumin for Symptomatic Adolescents With Bipolar Disorder: Brain and Body Considerations",[90],"2017-03-03",[35],[3315],{"trials":3331,"activeCount":101},[],{"trials":3333,"activeCount":101},[],{"trials":3335,"activeCount":101},[],{"intervention":3337,"totalTrials":155,"cells":3338},"Ondansetron",{"EARLY_PHASE1":3339,"PHASE1":3341,"PHASE2":3343,"PHASE3":3353,"PHASE4":3355,"NA":3357},{"trials":3340,"activeCount":101},[],{"trials":3342,"activeCount":101},[],{"trials":3344,"activeCount":101},[3345],{"nctId":3346,"briefTitle":3347,"status":219,"phases":3348,"primaryCompletion":3349,"completion":3349,"start":3350,"enrollment":16,"conditions":3351,"interventions":3352},"NCT02006056","Ondissolve in the Prophylaxis\u002FRescue of Radiation Induced Nausea and Vomiting",[90],"2014-06","2013-11",[2864,2865],[3337],{"trials":3354,"activeCount":101},[],{"trials":3356,"activeCount":101},[],{"trials":3358,"activeCount":101},[],{"intervention":3360,"totalTrials":155,"cells":3361},"Lenalidomide and melphalan",{"EARLY_PHASE1":3362,"PHASE1":3364,"PHASE2":3366,"PHASE3":3377,"PHASE4":3379,"NA":3381},{"trials":3363,"activeCount":101},[],{"trials":3365,"activeCount":101},[],{"trials":3367,"activeCount":101},[3368],{"nctId":3369,"briefTitle":3370,"status":219,"phases":3371,"primaryCompletion":3372,"completion":1928,"start":2376,"enrollment":615,"conditions":3373,"interventions":3376},"NCT00744536","Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS",[90],"2012-01",[2999,3374,3375],"Leukemia, Myelomonocytic, Chronic","Angiogenesis",[3360],{"trials":3378,"activeCount":101},[],{"trials":3380,"activeCount":101},[],{"trials":3382,"activeCount":101},[],{"intervention":1959,"totalTrials":155,"cells":3384},{"EARLY_PHASE1":3385,"PHASE1":3387,"PHASE2":3389,"PHASE3":3395,"PHASE4":3397,"NA":3399},{"trials":3386,"activeCount":101},[],{"trials":3388,"activeCount":101},[],{"trials":3390,"activeCount":101},[3391],{"nctId":1949,"briefTitle":1950,"status":622,"phases":3392,"primaryCompletion":1952,"completion":1953,"start":1954,"enrollment":1955,"conditions":3393,"interventions":3394},[90],[1957],[1940,1959],{"trials":3396,"activeCount":101},[],{"trials":3398,"activeCount":101},[],{"trials":3400,"activeCount":101},[],{"intervention":3402,"totalTrials":155,"cells":3403},"Homeopathic Potassium Dichromate",{"EARLY_PHASE1":3404,"PHASE1":3406,"PHASE2":3408,"PHASE3":3418,"PHASE4":3420,"NA":3422},{"trials":3405,"activeCount":101},[],{"trials":3407,"activeCount":101},[],{"trials":3409,"activeCount":101},[3410],{"nctId":3411,"briefTitle":3412,"status":209,"phases":3413,"primaryCompletion":1806,"completion":1806,"start":1618,"enrollment":3414,"conditions":3415,"interventions":3417},"NCT00425633","Efficacy Study of Homeopathic Potassium Dichromate to Treat Tracheal Secretions in Critically Ill Patients",[90],16,[3416],"Ventilator Adverse Event",[3402],{"trials":3419,"activeCount":101},[],{"trials":3421,"activeCount":101},[],{"trials":3423,"activeCount":101},[],{"intervention":723,"totalTrials":155,"cells":3425},{"EARLY_PHASE1":3426,"PHASE1":3428,"PHASE2":3430,"PHASE3":3436,"PHASE4":3438,"NA":3440},{"trials":3427,"activeCount":101},[],{"trials":3429,"activeCount":101},[],{"trials":3431,"activeCount":101},[3432],{"nctId":714,"briefTitle":715,"status":219,"phases":3433,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":3434,"interventions":3435},[90],[721],[696,723],{"trials":3437,"activeCount":101},[],{"trials":3439,"activeCount":101},[],{"trials":3441,"activeCount":101},[],{"intervention":3443,"totalTrials":155,"cells":3444},"Apremilast",{"EARLY_PHASE1":3445,"PHASE1":3447,"PHASE2":3449,"PHASE3":3460,"PHASE4":3462,"NA":3464},{"trials":3446,"activeCount":101},[],{"trials":3448,"activeCount":101},[],{"trials":3450,"activeCount":101},[3451],{"nctId":3452,"briefTitle":3453,"status":1461,"phases":3454,"primaryCompletion":3455,"completion":3455,"start":3456,"enrollment":101,"conditions":3457,"interventions":3459},"NCT03836885","Apremilast - Oral Lichen Planus Trial",[90],"2020-04-22","2019-11-21",[3458],"Oral Lichen Planus",[3443],{"trials":3461,"activeCount":101},[],{"trials":3463,"activeCount":101},[],{"trials":3465,"activeCount":101},[],{"intervention":3467,"totalTrials":155,"cells":3468},"N Acetylcysteine",{"EARLY_PHASE1":3469,"PHASE1":3471,"PHASE2":3473,"PHASE3":3483,"PHASE4":3485,"NA":3487},{"trials":3470,"activeCount":101},[],{"trials":3472,"activeCount":101},[],{"trials":3474,"activeCount":101},[3475],{"nctId":3476,"briefTitle":3477,"status":219,"phases":3478,"primaryCompletion":900,"completion":900,"start":3479,"enrollment":257,"conditions":3480,"interventions":3482},"NCT03306979","Memory and Antioxidants in Vascular Impairment Trial",[90],"2018-04-30",[3481],"Vascular Cognitive Impairment no Dementia",[3467],{"trials":3484,"activeCount":101},[],{"trials":3486,"activeCount":101},[],{"trials":3488,"activeCount":101},[],{"intervention":3490,"totalTrials":155,"cells":3491},"Trifluridine\u002FTipiracil",{"EARLY_PHASE1":3492,"PHASE1":3494,"PHASE2":3496,"PHASE3":3509,"PHASE4":3511,"NA":3513},{"trials":3493,"activeCount":101},[],{"trials":3495,"activeCount":101},[],{"trials":3497,"activeCount":101},[3498],{"nctId":3499,"briefTitle":3500,"status":209,"phases":3501,"primaryCompletion":3502,"completion":3502,"start":3503,"enrollment":3504,"conditions":3505,"interventions":3508},"NCT04076761","Study of TRIFLURIDINE\u002FTIPIRACIL in Previously Treated Cholangiocarcinoma",[90],"2022-09-30","2019-12-11",8,[3506,3507],"Cholangiocarcinoma","Bile Duct Cancer",[3490],{"trials":3510,"activeCount":101},[],{"trials":3512,"activeCount":101},[],{"trials":3514,"activeCount":101},[],{"intervention":3516,"totalTrials":155,"cells":3517},"Risperidone",{"EARLY_PHASE1":3518,"PHASE1":3520,"PHASE2":3522,"PHASE3":3533,"PHASE4":3535,"NA":3537},{"trials":3519,"activeCount":101},[],{"trials":3521,"activeCount":101},[],{"trials":3523,"activeCount":101},[3524],{"nctId":3525,"briefTitle":3526,"status":219,"phases":3527,"primaryCompletion":2947,"completion":2947,"start":1619,"enrollment":3528,"conditions":3529,"interventions":3531},"NCT01282632","Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression",[89,90],42,[3530],"Subjects Had Unipolar, Non-psychotic Major Depression",[3516,3532],"Olanzapine",{"trials":3534,"activeCount":101},[],{"trials":3536,"activeCount":101},[],{"trials":3538,"activeCount":101},[],{"intervention":3532,"totalTrials":155,"cells":3540},{"EARLY_PHASE1":3541,"PHASE1":3543,"PHASE2":3545,"PHASE3":3551,"PHASE4":3553,"NA":3555},{"trials":3542,"activeCount":101},[],{"trials":3544,"activeCount":101},[],{"trials":3546,"activeCount":101},[3547],{"nctId":3525,"briefTitle":3526,"status":219,"phases":3548,"primaryCompletion":2947,"completion":2947,"start":1619,"enrollment":3528,"conditions":3549,"interventions":3550},[89,90],[3530],[3516,3532],{"trials":3552,"activeCount":101},[],{"trials":3554,"activeCount":101},[],{"trials":3556,"activeCount":101},[],{"intervention":3558,"totalTrials":97,"cells":3559},"Hyperpolarized Pyruvate (13C)",{"EARLY_PHASE1":3560,"PHASE1":3562,"PHASE2":3581,"PHASE3":3583,"PHASE4":3585,"NA":3587},{"trials":3561,"activeCount":101},[],{"trials":3563,"activeCount":101},[3564,3572],{"nctId":3565,"briefTitle":3566,"status":1461,"phases":3567,"primaryCompletion":3568,"completion":3568,"start":1243,"enrollment":101,"conditions":3569,"interventions":3571},"NCT02647983","Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection",[89],"2019-10",[3570],"Prostatic Neoplasms",[3558],{"nctId":3573,"briefTitle":3574,"status":1461,"phases":3575,"primaryCompletion":3576,"completion":3576,"start":3577,"enrollment":101,"conditions":3578,"interventions":3579},"NCT03121989","Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy",[89],"2023-03-23","2017-11-21",[15],[3558,3580],"NAC",{"trials":3582,"activeCount":101},[],{"trials":3584,"activeCount":101},[],{"trials":3586,"activeCount":101},[],{"trials":3588,"activeCount":101},[],{"intervention":3590,"totalTrials":155,"cells":3591},"Visudyne",{"EARLY_PHASE1":3592,"PHASE1":3594,"PHASE2":3605,"PHASE3":3607,"PHASE4":3609,"NA":3611},{"trials":3593,"activeCount":101},[],{"trials":3595,"activeCount":101},[3596],{"nctId":3597,"briefTitle":3598,"status":219,"phases":3599,"primaryCompletion":3600,"completion":3600,"start":3601,"enrollment":16,"conditions":3602,"interventions":3604},"NCT02464761","Photodynamic Therapy for the Treatment of Vertebral Metastases",[89],"2017-09-07","2011-06",[3603],"Vertebral Metastases",[3590],{"trials":3606,"activeCount":101},[],{"trials":3608,"activeCount":101},[],{"trials":3610,"activeCount":101},[],{"trials":3612,"activeCount":101},[],{"intervention":3580,"totalTrials":155,"cells":3614},{"EARLY_PHASE1":3615,"PHASE1":3617,"PHASE2":3623,"PHASE3":3625,"PHASE4":3627,"NA":3629},{"trials":3616,"activeCount":101},[],{"trials":3618,"activeCount":101},[3619],{"nctId":3573,"briefTitle":3574,"status":1461,"phases":3620,"primaryCompletion":3576,"completion":3576,"start":3577,"enrollment":101,"conditions":3621,"interventions":3622},[89],[15],[3558,3580],{"trials":3624,"activeCount":101},[],{"trials":3626,"activeCount":101},[],{"trials":3628,"activeCount":101},[],{"trials":3630,"activeCount":101},[],{"intervention":3632,"totalTrials":155,"cells":3633},"Megestrol Acetate",{"EARLY_PHASE1":3634,"PHASE1":3636,"PHASE2":3648,"PHASE3":3650,"PHASE4":3652,"NA":3654},{"trials":3635,"activeCount":101},[],{"trials":3637,"activeCount":101},[3638],{"nctId":3639,"briefTitle":3640,"status":209,"phases":3641,"primaryCompletion":3642,"completion":3642,"start":3643,"enrollment":3644,"conditions":3645,"interventions":3647},"NCT05332483","Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer",[89],"2023-10-12","2022-07-05",5,[3646],"Endometrial Cancer",[3632],{"trials":3649,"activeCount":101},[],{"trials":3651,"activeCount":101},[],{"trials":3653,"activeCount":101},[],{"trials":3655,"activeCount":101},[],{"intervention":3657,"totalTrials":155,"cells":3658},"collagenase",{"EARLY_PHASE1":3659,"PHASE1":3661,"PHASE2":3674,"PHASE3":3676,"PHASE4":3678,"NA":3680},{"trials":3660,"activeCount":101},[],{"trials":3662,"activeCount":101},[3663],{"nctId":3664,"briefTitle":3665,"status":219,"phases":3666,"primaryCompletion":3667,"completion":3668,"start":3669,"enrollment":3670,"conditions":3671,"interventions":3673},"NCT01271335","Collagenase Total Occlusion-1 Trial",[89],"2011-09","2012-02","2009-11",28,[3672],"Chronic Total Occlusions",[3657],{"trials":3675,"activeCount":101},[],{"trials":3677,"activeCount":101},[],{"trials":3679,"activeCount":101},[],{"trials":3681,"activeCount":101},[],{"intervention":1164,"totalTrials":155,"cells":3683},{"EARLY_PHASE1":3684,"PHASE1":3686,"PHASE2":3692,"PHASE3":3694,"PHASE4":3696,"NA":3698},{"trials":3685,"activeCount":101},[],{"trials":3687,"activeCount":101},[3688],{"nctId":1155,"briefTitle":1156,"status":209,"phases":3689,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":3690,"interventions":3691},[89],[1162],[1139,1164],{"trials":3693,"activeCount":101},[],{"trials":3695,"activeCount":101},[],{"trials":3697,"activeCount":101},[],{"trials":3699,"activeCount":101},[],{"intervention":3701,"totalTrials":155,"cells":3702},"Feraheme®",{"EARLY_PHASE1":3703,"PHASE1":3714,"PHASE2":3716,"PHASE3":3718,"PHASE4":3720,"NA":3722},{"trials":3704,"activeCount":101},[3705],{"nctId":3706,"briefTitle":3707,"status":219,"phases":3708,"primaryCompletion":3709,"completion":3709,"start":3710,"enrollment":31,"conditions":3711,"interventions":3713},"NCT02466828","qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.",[88],"2018-04","2015-03",[946,3712],"Hypoxia",[3701],{"trials":3715,"activeCount":101},[],{"trials":3717,"activeCount":101},[],{"trials":3719,"activeCount":101},[],{"trials":3721,"activeCount":101},[],{"trials":3723,"activeCount":101},[],{"intervention":3725,"totalTrials":155,"cells":3726},"Desmopressin",{"EARLY_PHASE1":3727,"PHASE1":3739,"PHASE2":3741,"PHASE3":3743,"PHASE4":3745,"NA":3747},{"trials":3728,"activeCount":101},[3729],{"nctId":3730,"briefTitle":3731,"status":622,"phases":3732,"primaryCompletion":3733,"completion":3734,"start":3735,"enrollment":31,"conditions":3736,"interventions":3738},"NCT04113005","Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer",[88],"2020-04-30","2020-10-01","2019-10-01",[3737],"Castrate Resistance Prostate Cancer",[3725],{"trials":3740,"activeCount":101},[],{"trials":3742,"activeCount":101},[],{"trials":3744,"activeCount":101},[],{"trials":3746,"activeCount":101},[],{"trials":3748,"activeCount":101},[],{"intervention":328,"totalTrials":155,"cells":3750},{"EARLY_PHASE1":3751,"PHASE1":3757,"PHASE2":3759,"PHASE3":3761,"PHASE4":3763,"NA":3765},{"trials":3752,"activeCount":101},[3753],{"nctId":318,"briefTitle":319,"status":219,"phases":3754,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":3755,"interventions":3756},[88],[326],[328,329],{"trials":3758,"activeCount":101},[],{"trials":3760,"activeCount":101},[],{"trials":3762,"activeCount":101},[],{"trials":3764,"activeCount":101},[],{"trials":3766,"activeCount":101},[],{"intervention":3768,"totalTrials":97,"cells":3769},"Metformin",{"EARLY_PHASE1":3770,"PHASE1":3772,"PHASE2":3774,"PHASE3":3785,"PHASE4":3787,"NA":3789},{"trials":3771,"activeCount":101},[],{"trials":3773,"activeCount":101},[],{"trials":3775,"activeCount":101},[3776],{"nctId":3777,"briefTitle":3778,"status":219,"phases":3779,"primaryCompletion":3780,"completion":3780,"start":3781,"enrollment":2591,"conditions":3782,"interventions":3784},"NCT03053544","Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer",[90],"2019-06-26","2016-12-08",[3783],"Rectal Neoplasm Carcinoma in Situ Adenocarcinoma",[3768],{"trials":3786,"activeCount":101},[],{"trials":3788,"activeCount":101},[],{"trials":3790,"activeCount":101},[3791],{"nctId":3792,"briefTitle":3793,"status":219,"phases":3794,"primaryCompletion":3795,"completion":3795,"start":3796,"enrollment":3797,"conditions":3798,"interventions":3800},"NCT01307306","Glucose Control in Severely Burned Patients",[93],"2018-03","2011-03",45,[3799],"Burns",[3801,3768],"Humulin R",{"intervention":3803,"totalTrials":155,"cells":3804},"Perflutren lipid microsphere",{"EARLY_PHASE1":3805,"PHASE1":3807,"PHASE2":3809,"PHASE3":3811,"PHASE4":3813,"NA":3815},{"trials":3806,"activeCount":101},[],{"trials":3808,"activeCount":101},[],{"trials":3810,"activeCount":101},[],{"trials":3812,"activeCount":101},[],{"trials":3814,"activeCount":101},[],{"trials":3816,"activeCount":101},[3817],{"nctId":3818,"briefTitle":3819,"status":209,"phases":3820,"primaryCompletion":2661,"completion":2661,"start":3667,"enrollment":25,"conditions":3821,"interventions":3823},"NCT01391039","Diagnostic Study of Early Breast Cancer Using Ultrasound",[93],[3822],"Ductal Carcinoma In-situ",[3803],{"intervention":3825,"totalTrials":155,"cells":3826},"Collagenase clostridium histolyticum",{"EARLY_PHASE1":3827,"PHASE1":3829,"PHASE2":3831,"PHASE3":3833,"PHASE4":3835,"NA":3837},{"trials":3828,"activeCount":101},[],{"trials":3830,"activeCount":101},[],{"trials":3832,"activeCount":101},[],{"trials":3834,"activeCount":101},[],{"trials":3836,"activeCount":101},[],{"trials":3838,"activeCount":101},[3839],{"nctId":3840,"briefTitle":3841,"status":622,"phases":3842,"primaryCompletion":3843,"completion":3844,"start":3845,"enrollment":257,"conditions":3846,"interventions":3848},"NCT02301078","Short-term Function and Pain After Treatment for Dupuytren's Disease",[],"2017-10","2017-11","2014-07",[3847],"Dupuytren Disease",[3825],{"intervention":3850,"totalTrials":155,"cells":3851},"Half Normal Saline 0.45% Infusion Solution Bag",{"EARLY_PHASE1":3852,"PHASE1":3854,"PHASE2":3856,"PHASE3":3858,"PHASE4":3860,"NA":3862},{"trials":3853,"activeCount":101},[],{"trials":3855,"activeCount":101},[],{"trials":3857,"activeCount":101},[],{"trials":3859,"activeCount":101},[],{"trials":3861,"activeCount":101},[],{"trials":3863,"activeCount":101},[3864],{"nctId":3865,"briefTitle":3866,"status":219,"phases":3867,"primaryCompletion":3868,"completion":3868,"start":3869,"enrollment":1160,"conditions":3870,"interventions":3872},"NCT04001530","Half-normal Saline in Atrial Flutter Ablation",[93],"2021-01-31","2018-01-01",[3871],"Atrial Flutter",[3850,3873],"Normal Saline 0.9% Infusion Solution Bag",{"intervention":3873,"totalTrials":155,"cells":3875},{"EARLY_PHASE1":3876,"PHASE1":3878,"PHASE2":3880,"PHASE3":3882,"PHASE4":3884,"NA":3886},{"trials":3877,"activeCount":101},[],{"trials":3879,"activeCount":101},[],{"trials":3881,"activeCount":101},[],{"trials":3883,"activeCount":101},[],{"trials":3885,"activeCount":101},[],{"trials":3887,"activeCount":101},[3888],{"nctId":3865,"briefTitle":3866,"status":219,"phases":3889,"primaryCompletion":3868,"completion":3868,"start":3869,"enrollment":1160,"conditions":3890,"interventions":3891},[93],[3871],[3850,3873],{"intervention":3893,"totalTrials":155,"cells":3894},"Ozurdex",{"EARLY_PHASE1":3895,"PHASE1":3897,"PHASE2":3899,"PHASE3":3901,"PHASE4":3903,"NA":3905},{"trials":3896,"activeCount":101},[],{"trials":3898,"activeCount":101},[],{"trials":3900,"activeCount":101},[],{"trials":3902,"activeCount":101},[],{"trials":3904,"activeCount":101},[],{"trials":3906,"activeCount":101},[3907],{"nctId":3908,"briefTitle":3909,"status":622,"phases":3910,"primaryCompletion":2816,"completion":2724,"start":3911,"enrollment":2591,"conditions":3912,"interventions":3915},"NCT01701518","A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes",[93],"2012-10",[3913,3914],"Epiretinal Membrane","Macular Edema",[3893],{"intervention":3917,"totalTrials":155,"cells":3918},"ketamine hydrochloride",{"EARLY_PHASE1":3919,"PHASE1":3921,"PHASE2":3923,"PHASE3":3925,"PHASE4":3927,"NA":3929},{"trials":3920,"activeCount":101},[],{"trials":3922,"activeCount":101},[],{"trials":3924,"activeCount":101},[],{"trials":3926,"activeCount":101},[],{"trials":3928,"activeCount":101},[],{"trials":3930,"activeCount":101},[3931],{"nctId":3932,"briefTitle":3933,"status":219,"phases":3934,"primaryCompletion":3935,"completion":3935,"start":3936,"enrollment":3937,"conditions":3938,"interventions":3940},"NCT07099235","Chart Review of Patients Undergoing Ketamine Treatments for Depression",[],"2025-06-29","2022-04-01",250,[3939],"Depression - Major Depressive Disorder",[3917],{"intervention":3942,"totalTrials":155,"cells":3943},"Plasma HPV",{"EARLY_PHASE1":3944,"PHASE1":3946,"PHASE2":3948,"PHASE3":3950,"PHASE4":3952,"NA":3954},{"trials":3945,"activeCount":101},[],{"trials":3947,"activeCount":101},[],{"trials":3949,"activeCount":101},[],{"trials":3951,"activeCount":101},[],{"trials":3953,"activeCount":101},[],{"trials":3955,"activeCount":101},[3956],{"nctId":3957,"briefTitle":3958,"status":622,"phases":3959,"primaryCompletion":3960,"completion":3961,"start":3962,"enrollment":3963,"conditions":3964,"interventions":3966},"NCT02388698","FDG-PET and Circulating HPV in Patients With Cervical Cancer",[93],"2019-12","2023-12","2016-11-23",84,[3965],"Cervical Cancer",[3942],{"intervention":3801,"totalTrials":155,"cells":3968},{"EARLY_PHASE1":3969,"PHASE1":3971,"PHASE2":3973,"PHASE3":3975,"PHASE4":3977,"NA":3979},{"trials":3970,"activeCount":101},[],{"trials":3972,"activeCount":101},[],{"trials":3974,"activeCount":101},[],{"trials":3976,"activeCount":101},[],{"trials":3978,"activeCount":101},[],{"trials":3980,"activeCount":101},[3981],{"nctId":3792,"briefTitle":3793,"status":219,"phases":3982,"primaryCompletion":3795,"completion":3795,"start":3796,"enrollment":3797,"conditions":3983,"interventions":3984},[93],[3799],[3801,3768],{"intervention":3986,"totalTrials":155,"cells":3987},"propranolol",{"EARLY_PHASE1":3988,"PHASE1":3990,"PHASE2":3992,"PHASE3":3994,"PHASE4":3996,"NA":3998},{"trials":3989,"activeCount":101},[],{"trials":3991,"activeCount":101},[],{"trials":3993,"activeCount":101},[],{"trials":3995,"activeCount":101},[],{"trials":3997,"activeCount":101},[],{"trials":3999,"activeCount":101},[4000],{"nctId":4001,"briefTitle":4002,"status":622,"phases":4003,"primaryCompletion":1893,"completion":4004,"start":4005,"enrollment":324,"conditions":4006,"interventions":4007},"NCT01299753","Catecholamine Blockade Post-burn",[93],"2023-12-31","2011-02",[3799],[3986],{"intervention":4009,"totalTrials":155,"cells":4010},"prostaglandin of the clinician's choice",{"EARLY_PHASE1":4011,"PHASE1":4013,"PHASE2":4015,"PHASE3":4017,"PHASE4":4019,"NA":4021},{"trials":4012,"activeCount":101},[],{"trials":4014,"activeCount":101},[],{"trials":4016,"activeCount":101},[],{"trials":4018,"activeCount":101},[],{"trials":4020,"activeCount":101},[],{"trials":4022,"activeCount":101},[4023],{"nctId":4024,"briefTitle":4025,"status":622,"phases":4026,"primaryCompletion":3960,"completion":3960,"start":2724,"enrollment":4027,"conditions":4028,"interventions":4032},"NCT02993432","High Volume Foleys Increasing Vaginal Birth Pilot Trial",[93],130,[4029,4030,4031],"Labour; Induced","Pilot Study","Cervical Ripening",[4009],{"intervention":4034,"totalTrials":155,"cells":4035},"Unfractionated heparin",{"EARLY_PHASE1":4036,"PHASE1":4038,"PHASE2":4040,"PHASE3":4042,"PHASE4":4044,"NA":4046},{"trials":4037,"activeCount":101},[],{"trials":4039,"activeCount":101},[],{"trials":4041,"activeCount":101},[],{"trials":4043,"activeCount":101},[],{"trials":4045,"activeCount":101},[],{"trials":4047,"activeCount":101},[4048],{"nctId":4049,"briefTitle":4050,"status":622,"phases":4051,"primaryCompletion":4052,"completion":280,"start":4053,"enrollment":19,"conditions":4054,"interventions":4059},"NCT04121611","Optical Coherence Tomography Guided Antithrombotic Treatment After Endovascular Thrombectomy of the Posterior Circulation",[93],"2021-10-14","2019-10-14",[4055,4056,4057,4058],"Stroke of Basilar Artery","Optical Coherence Tomography","Antithrombotics","Endovascular Thrombectomy",[4034,4060],"Acetylsalicylic Acid",{"intervention":4060,"totalTrials":155,"cells":4062},{"EARLY_PHASE1":4063,"PHASE1":4065,"PHASE2":4067,"PHASE3":4069,"PHASE4":4071,"NA":4073},{"trials":4064,"activeCount":101},[],{"trials":4066,"activeCount":101},[],{"trials":4068,"activeCount":101},[],{"trials":4070,"activeCount":101},[],{"trials":4072,"activeCount":101},[],{"trials":4074,"activeCount":101},[4075],{"nctId":4049,"briefTitle":4050,"status":622,"phases":4076,"primaryCompletion":4052,"completion":280,"start":4053,"enrollment":19,"conditions":4077,"interventions":4078},[93],[4055,4056,4057,4058],[4034,4060],{"intervention":4080,"totalTrials":155,"cells":4081},"Cholinesterase Inhibitors",{"EARLY_PHASE1":4082,"PHASE1":4084,"PHASE2":4086,"PHASE3":4088,"PHASE4":4090,"NA":4092},{"trials":4083,"activeCount":101},[],{"trials":4085,"activeCount":101},[],{"trials":4087,"activeCount":101},[],{"trials":4089,"activeCount":101},[],{"trials":4091,"activeCount":101},[],{"trials":4093,"activeCount":101},[4094],{"nctId":4095,"briefTitle":4096,"status":219,"phases":4097,"primaryCompletion":366,"completion":366,"start":1496,"enrollment":2132,"conditions":4098,"interventions":4100},"NCT01944436","A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease",[],[4099],"Lewy Body Disease",[4080],{"intervention":4102,"totalTrials":155,"cells":4103},"Genetic Mutations",{"EARLY_PHASE1":4104,"PHASE1":4106,"PHASE2":4108,"PHASE3":4110,"PHASE4":4112,"NA":4114},{"trials":4105,"activeCount":101},[],{"trials":4107,"activeCount":101},[],{"trials":4109,"activeCount":101},[],{"trials":4111,"activeCount":101},[],{"trials":4113,"activeCount":101},[],{"trials":4115,"activeCount":101},[4116],{"nctId":4117,"briefTitle":4118,"status":622,"phases":4119,"primaryCompletion":2814,"completion":2814,"start":4120,"enrollment":4121,"conditions":4122,"interventions":4126},"NCT04110925","Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia",[93],"2019-09",400,[4123,4124,4125],"MDS","Cardiovascular Diseases","Inflammation",[4102],{"intervention":4128,"totalTrials":155,"cells":4129},"sulfur hexafluoride",{"EARLY_PHASE1":4130,"PHASE1":4132,"PHASE2":4134,"PHASE3":4136,"PHASE4":4138,"NA":4140},{"trials":4131,"activeCount":101},[],{"trials":4133,"activeCount":101},[],{"trials":4135,"activeCount":101},[],{"trials":4137,"activeCount":101},[],{"trials":4139,"activeCount":101},[],{"trials":4141,"activeCount":101},[4142],{"nctId":4143,"briefTitle":4144,"status":622,"phases":4145,"primaryCompletion":4146,"completion":2661,"start":3845,"enrollment":16,"conditions":4147,"interventions":4149},"NCT02185469","Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment",[93],"2015-06",[4148],"Rhegmatogenous Retinal Detachment",[4128],{"intervention":4151,"totalTrials":155,"cells":4152},"Cheek swab samples for DNA",{"EARLY_PHASE1":4153,"PHASE1":4155,"PHASE2":4157,"PHASE3":4159,"PHASE4":4161,"NA":4163},{"trials":4154,"activeCount":101},[],{"trials":4156,"activeCount":101},[],{"trials":4158,"activeCount":101},[],{"trials":4160,"activeCount":101},[],{"trials":4162,"activeCount":101},[],{"trials":4164,"activeCount":101},[4165],{"nctId":4166,"briefTitle":4167,"status":219,"phases":4168,"completion":2264,"start":1463,"enrollment":4169,"conditions":4170,"interventions":4172},"NCT00327431","Relationship of Genes and Life Events to Blood Pressure",[],120,[27,4171],"Psychosocial Factors",[4151],{"intervention":4174,"totalTrials":155,"cells":4175},"Direct Acting Oral Anticoagulant starting at Day 30",{"EARLY_PHASE1":4176,"PHASE1":4178,"PHASE2":4180,"PHASE3":4182,"PHASE4":4184,"NA":4186},{"trials":4177,"activeCount":101},[],{"trials":4179,"activeCount":101},[],{"trials":4181,"activeCount":101},[],{"trials":4183,"activeCount":101},[],{"trials":4185,"activeCount":101},[],{"trials":4187,"activeCount":101},[4188],{"nctId":4189,"briefTitle":4190,"status":209,"phases":4191,"primaryCompletion":4192,"completion":4193,"start":4194,"enrollment":155,"conditions":4195,"interventions":4198},"NCT05472766","Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma",[93],"2024-03-22","2024-05-10","2022-11-24",[4196,4197],"Subdural Hematoma","Atrial Fibrillation",[4174,4199],"Direct Acting Oral Anticoagulant starting at Day 90",{"intervention":4199,"totalTrials":155,"cells":4201},{"EARLY_PHASE1":4202,"PHASE1":4204,"PHASE2":4206,"PHASE3":4208,"PHASE4":4210,"NA":4212},{"trials":4203,"activeCount":101},[],{"trials":4205,"activeCount":101},[],{"trials":4207,"activeCount":101},[],{"trials":4209,"activeCount":101},[],{"trials":4211,"activeCount":101},[],{"trials":4213,"activeCount":101},[4214],{"nctId":4189,"briefTitle":4190,"status":209,"phases":4215,"primaryCompletion":4192,"completion":4193,"start":4194,"enrollment":155,"conditions":4216,"interventions":4217},[93],[4196,4197],[4174,4199],{"intervention":4219,"totalTrials":155,"cells":4220},"Bupivacaine hydrogen chloride , epinephrine",{"EARLY_PHASE1":4221,"PHASE1":4223,"PHASE2":4225,"PHASE3":4227,"PHASE4":4229,"NA":4231},{"trials":4222,"activeCount":101},[],{"trials":4224,"activeCount":101},[],{"trials":4226,"activeCount":101},[],{"trials":4228,"activeCount":101},[],{"trials":4230,"activeCount":101},[],{"trials":4232,"activeCount":101},[4233],{"nctId":4234,"briefTitle":4235,"status":622,"phases":4236,"primaryCompletion":4237,"completion":4238,"start":4239,"enrollment":4169,"conditions":4240,"interventions":4242},"NCT03094481","Interscalene vs. Superficial Cervical Block vs. Combination for Analgesia After Clavicle Fracture",[93],"2019-11-01","2020-03-01","2016-10-21",[4241],"Clavicle Fracture",[4219],{"intervention":4244,"totalTrials":155,"cells":4245},"Bupivacaine 0.5%+Epinephrine 50mc",{"EARLY_PHASE1":4246,"PHASE1":4248,"PHASE2":4250,"PHASE3":4252,"PHASE4":4254,"NA":4256},{"trials":4247,"activeCount":101},[],{"trials":4249,"activeCount":101},[],{"trials":4251,"activeCount":101},[],{"trials":4253,"activeCount":101},[],{"trials":4255,"activeCount":101},[],{"trials":4257,"activeCount":101},[4258],{"nctId":4259,"briefTitle":4260,"status":209,"phases":4261,"primaryCompletion":4262,"completion":4262,"start":4263,"enrollment":1917,"conditions":4264,"interventions":4268},"NCT03672500","Perineal Local Infiltration Study",[93],"2022-05-09","2018-09-14",[4265,4266,4267],"Second Degree Perineal Tear During Delivery - Delivered","Episiotomy; Complications","Anesthesia, Local",[4244],{"intervention":4270,"totalTrials":155,"cells":4271},"Bupivacaine",{"EARLY_PHASE1":4272,"PHASE1":4274,"PHASE2":4276,"PHASE3":4278,"PHASE4":4280,"NA":4282},{"trials":4273,"activeCount":101},[],{"trials":4275,"activeCount":101},[],{"trials":4277,"activeCount":101},[],{"trials":4279,"activeCount":101},[],{"trials":4281,"activeCount":101},[],{"trials":4283,"activeCount":101},[4284],{"nctId":4285,"briefTitle":4286,"status":219,"phases":4287,"primaryCompletion":4288,"completion":4288,"start":4289,"enrollment":4290,"conditions":4291,"interventions":4294},"NCT03266926","Does the Use of Bupivacaine Soaked Vaginal Packing Following Vaginal Surgery Decrease Postoperative Pain?",[],"2018-03-01","2017-02-01",140,[4292,4293],"Pelvic Organ Prolapse","Postoperative Pain",[4270,4295],"Premarin Vaginal cream",{"intervention":4295,"totalTrials":155,"cells":4297},{"EARLY_PHASE1":4298,"PHASE1":4300,"PHASE2":4302,"PHASE3":4304,"PHASE4":4306,"NA":4308},{"trials":4299,"activeCount":101},[],{"trials":4301,"activeCount":101},[],{"trials":4303,"activeCount":101},[],{"trials":4305,"activeCount":101},[],{"trials":4307,"activeCount":101},[],{"trials":4309,"activeCount":101},[4310],{"nctId":4285,"briefTitle":4286,"status":219,"phases":4311,"primaryCompletion":4288,"completion":4288,"start":4289,"enrollment":4290,"conditions":4312,"interventions":4313},[],[4292,4293],[4270,4295],{"intervention":228,"totalTrials":155,"cells":4315},{"EARLY_PHASE1":4316,"PHASE1":4318,"PHASE2":4320,"PHASE3":4322,"PHASE4":4324,"NA":4326},{"trials":4317,"activeCount":101},[],{"trials":4319,"activeCount":101},[],{"trials":4321,"activeCount":101},[],{"trials":4323,"activeCount":101},[],{"trials":4325,"activeCount":101},[],{"trials":4327,"activeCount":101},[4328],{"nctId":217,"briefTitle":218,"status":219,"phases":4329,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":4330,"interventions":4331},[93],[226],[228,229,230],{"intervention":229,"totalTrials":155,"cells":4333},{"EARLY_PHASE1":4334,"PHASE1":4336,"PHASE2":4338,"PHASE3":4340,"PHASE4":4342,"NA":4344},{"trials":4335,"activeCount":101},[],{"trials":4337,"activeCount":101},[],{"trials":4339,"activeCount":101},[],{"trials":4341,"activeCount":101},[],{"trials":4343,"activeCount":101},[],{"trials":4345,"activeCount":101},[4346],{"nctId":217,"briefTitle":218,"status":219,"phases":4347,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":4348,"interventions":4349},[93],[226],[228,229,230],{"intervention":4351,"totalTrials":155,"cells":4352},"Ropivacaine 0.5%",{"EARLY_PHASE1":4353,"PHASE1":4355,"PHASE2":4357,"PHASE3":4359,"PHASE4":4361,"NA":4363},{"trials":4354,"activeCount":101},[],{"trials":4356,"activeCount":101},[],{"trials":4358,"activeCount":101},[],{"trials":4360,"activeCount":101},[],{"trials":4362,"activeCount":101},[],{"trials":4364,"activeCount":101},[4365],{"nctId":4366,"briefTitle":4367,"status":219,"phases":4368,"primaryCompletion":410,"completion":4369,"start":366,"enrollment":257,"conditions":4370,"interventions":4373},"NCT02643563","Analgesic Duration of Long Acting Local Anesthetics for Low Volume Ultrasound-guided Interscalene Brachial Plexus Block",[93],"2019-04",[4371,4372],"Brachial Plexus Block","Anesthetics, Local",[4351,4374,4375],"Ropivacaine 1%","Bupivacaine 0.5% + epinephrine 1:200,000",{"intervention":4374,"totalTrials":155,"cells":4377},{"EARLY_PHASE1":4378,"PHASE1":4380,"PHASE2":4382,"PHASE3":4384,"PHASE4":4386,"NA":4388},{"trials":4379,"activeCount":101},[],{"trials":4381,"activeCount":101},[],{"trials":4383,"activeCount":101},[],{"trials":4385,"activeCount":101},[],{"trials":4387,"activeCount":101},[],{"trials":4389,"activeCount":101},[4390],{"nctId":4366,"briefTitle":4367,"status":219,"phases":4391,"primaryCompletion":410,"completion":4369,"start":366,"enrollment":257,"conditions":4392,"interventions":4393},[93],[4371,4372],[4351,4374,4375],{"intervention":4375,"totalTrials":155,"cells":4395},{"EARLY_PHASE1":4396,"PHASE1":4398,"PHASE2":4400,"PHASE3":4402,"PHASE4":4404,"NA":4406},{"trials":4397,"activeCount":101},[],{"trials":4399,"activeCount":101},[],{"trials":4401,"activeCount":101},[],{"trials":4403,"activeCount":101},[],{"trials":4405,"activeCount":101},[],{"trials":4407,"activeCount":101},[4408],{"nctId":4366,"briefTitle":4367,"status":219,"phases":4409,"primaryCompletion":410,"completion":4369,"start":366,"enrollment":257,"conditions":4410,"interventions":4411},[93],[4371,4372],[4351,4374,4375],{"intervention":4413,"totalTrials":155,"cells":4414},"Dutasteride",{"EARLY_PHASE1":4415,"PHASE1":4417,"PHASE2":4419,"PHASE3":4421,"PHASE4":4423,"NA":4425},{"trials":4416,"activeCount":101},[],{"trials":4418,"activeCount":101},[],{"trials":4420,"activeCount":101},[],{"trials":4422,"activeCount":101},[],{"trials":4424,"activeCount":101},[],{"trials":4426,"activeCount":101},[4427],{"nctId":4428,"briefTitle":4429,"status":219,"phases":4430,"primaryCompletion":4431,"completion":4431,"start":1475,"enrollment":1383,"conditions":4432,"interventions":4433},"NCT01525914","Response of Patients on Surveillance for Prostate Cancer to Dutasteride",[],"2010-08",[18],[4413]]